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SUMMARY 
 
Sugars, amino acids and lipids provide the energy and building blocks for growth and maintenance in all 
animals. However, animal species display great variation in their dietary preferences. The optimal diet of 
even closely related species can vary tremendously. Also human populations and individuals vary in their 
dietary behavior and physiological responses to dietary interventions. Moreover, the high amounts of 
refined sugars in the modern human diet are suggested to contribute to the development of metabolic 
diseases such as metabolic syndrome and type 2 diabetes.  
 
Multicellular animals sense and control their energy homeostasis continuously by integrating nutritional, 
hormonal and neuronal inputs from their internal and external environment. For example, the counteracting 
hormones Insulin and Glucagon maintain the levels of circulating glucose constant during fluctuating 
nutritional conditions. At the cellular level, macronutrients are sensed by distinct mechanisms. The nutrient 
sensors and their downstream signaling pathways are activated in response to specific nutrients, and they 
ensure the metabolic homeostasis. Sugars are sensed by highly conserved transcription factor paralogs 
ChREBP (Carbohydrate-responsive element-binding protein) and MondoA, which share the same 
heterodimerization partner Mlx. ChREBP/MondoA-Mlx heterodimers regulate the majority of sugar-
induced transcription in mammals, including genes of the glycolytic and lipogenic pathways. Dysregulation 
of ChREBP has been associated with the development of type 2 diabetes, and polymorphisms of ChREBP 
with circulating triglyceride levels and increased risk of coronary artery disease.  
 
The Drosophila genome encodes single orthologues for ChREBP/MondoA and Mlx called Mondo and Mlx, 
respectively. The function of the mammalian ChREBP/MondoA-Mlx has been largely studied in vitro. The 
aim of this thesis was to characterize the in vivo function of Drosophila Mondo-Mlx and to identify its 
target genes and their roles in regulating sugar metabolism. Due to the lack of genetic redundancy and with 
the extensive toolkit available, the Drosophila provides an optimal in vivo model for studying the role of 
Mondo-Mlx in nutrient sensing and metabolism.  
 
In this thesis, I demonstrate the physiological importance of Mondo-Mlx for organismal sugar tolerance. 
The mlx null mutant animals display severe sugar intolerance and a gene expression profile that confirms 
the role of Mondo-Mlx as a key regulator of glycolytic and lipogenic genes also in Drosophila. Furthermore, 
we expand the role of Mondo-Mlx as a metabolic regulator by showing that it directly controls the 
expression of several key enzymes of lipid storage, pentose phosphate pathway and amino acid metabolism 
in response sugars. We also show that Mondo-Mlx is a master regulator of a gene regulatory network 
composed of a secondary tier of transcriptional effectors including GLI similar transcription factor 
Sugarbabe and Krüppel-like factor Cabut. The metabolic profiling of the mlx null mutant animals revealed 
that in addition to being hyperglycaemic, the mutants show signs of amino acid catabolism and elevated 
ceramide levels that indicate lipotoxicity. 
 
This thesis demonstrates the use of Drosophila in studying the genetic basis of dietary sugar tolerance and 
metabolism. It reveals a number of new metabolic pathways and downstream effectors regulated by Mondo-
Mlx, broadening its role as a master regulator of sugar-induced transcription. 
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YHTEENVETO 
 
Ravinnosta saatavat sokerit, aminohapot ja rasvat tarjoavat kaikille eliöille paitsi energiaa, myös tarvittavat 
rakennuspalikat kudosten kasvuun ja ylläpitoon. Eliöt poikkeavat huomattavasti toisistaan niille sopivan 
ravinnon suhteen ja aivan lähisukuisetkin lajit saattavat suosia hyvin erilaista ravintoa. Myös ihmiset ja 
ihmispopulaatiot poikkeavat ravintokäyttäytymisessä toisistaan. Nykyisen länsimaisen ravinnon, joka pitää 
sisällään huomattavan määrän puhdistettuja sokereita, on ehdotettu olevan tyypin 2 diabeteksen sekä 
metabolisen syndrooman yleistymisen taustalla. 
 
Eläimet aistivat ja kontrolloivat aineenvaihdunnan tasapainoa yhdistämällä hormonaalisia, hermostollisia 
sekä ravintoperäisiä signaaleja kehosta ja ympäristöstä. Esimerkiksi haiman erittämät vastavaikutteiset 
hormonit, insuliini ja glukagoni, säätelevät systeemisellä tasolla veren glukoosipitoisuutta. Solutasolla 
ravinnon aistinnasta vastaavat niin sanotut ”ravintosensorit”, jotka tunnistavat tiettyjä ravintoaineita ja 
aktivoivat signalointireittejä, jotka puolestaan säätelevät koko kehon aineenvaihdunnan tasapainoa eli 
homeostaasia. Solutasolla ravinnon sokereiden aistinnasta vastaavat konservoituneet ChREBP ja MondoA 
transkriptiotekijät, jotka yhdessä saman sitoutumiskumppaninsa, Mlx:n kanssa säätelevät valtaosaa sokeri-
indusoituvasta geenien ilmentymisestä nisäkkäillä. ChREBP/MondoA-Mlx kohdegeeneihin lukeutuu muun 
muassa useita glykolyysin ja rasvasynteesin entsyymejä. ChREBP:n toiminnan häiriöt on yhdistetty 
ihmisillä tyypin 2 diabeteksen syntyyn. Lisäksi ChREBP varianttien (SNP) on havaittu olevan yhteydessä 
sepelvaltimotaudin syntyyn, sekä plasman triglyseridien määrään.  
 
Toisin kuin nisäkkäillä, banaanikärpäsellä (Drosophila) on vain yksi ChREBP/MondoA paralogi, Mondo. 
ChREBP/MondoA-Mlx:n toimintaa on tutkittu nisäkkäillä lähinnä soluviljelyolosuhteissa ja tämän 
väitöskirjan tavoitteena oli karakterisoida banaanikärpäsen Mondo-Mlx transkriptiotekijöiden toiminta in 
vivo. Lisäksi selvitimme Mondo-Mlx kohdegeenejä, sekä tutkimme niiden toimintaa 
sokeriaineenvaihdunnan säätelyssä. Banaanikärpänen on erinomainen malli Mondo-Mlx:n toiminnan 
tutkimiseen paitsi mahdollisen redundanssin puuttumisen, myös erilaisten geneettisten työkalujen valtavan 
määrän ansioista.  
 
Osoitan tässä väitöskirjassa Mondo-Mlx transkriptiotekijöiden olevan välttämättömiä banaanikärpäsen 
sokeritoleranssille. Mlx mutanttikärpäset ovat herkkiä ravinnon sokereille ja jo suhteellisen pienet määrät 
sokeria johtavat mlx1 mutanttien kuolemaan kehityksen varhaisessa vaiheessa, sekä selvästi kohonneeseen 
veren (hemolymfa) glukoosipitoisuuteen. Geeniekspressioanalyysi varmisti Mondo-Mlx:n tärkeän roolin 
glykolyysin ja lipidisynteesin entsyymien säätelijänä myös banaanikärpäsessä. Nisäkästutkimuksissa 
aiemmin löydettyjen kohdegeenien lisäksi havaitsin Mondo-Mlx:n säätelevän myös muun muassa rasvojen 
varastointiin ja aminohappoaineenvaihduntaan liittyvien geenien ilmentymistä. Lisäksi havaitsin Mondo-
Mlx:n säätelevän monien transkriptiotekijöiden ilmentymistä, jotka puolestaan säätelevät osaa Mondo-
Mlx:n alavirran kohdegeeneistä. Mlx mutanttitoukkien metabolinen profilointi paljasti myös monia muita 
aineenvaihdunnan muutoksia. Alentuneet aminohappotasot sekä kohonneet ureapitoisuudet viittaavat 
siihen, että mlx1 mutantit käyttävät aminohappoja energialähteenään.  
 
Tämä väitöskirja osoittaa banaanikärpäsen olevan geneettisesti sekä fysiologisesti ihanteellinen malli 
sokeriaineenvaihdunnan tutkimiseen. Löysin työssäni useita uusia Mondo-Mlx säädeltyjä 
aineenvaihdunnan reittejä ja kohdegeenejä. Nämä tulokset laajentavat käsitystä ChREBP/MondoA-Mlx:n 
roolista aineenvaihdunnan säätelijänä.
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1. INTRODUCTION 
1.1. Nutrient sensing and metabolic homeostasis 
Sugars, amino acids and lipids, collectively termed 
macronutrients, are consumed by all animals to 
provide energy and building blocks for 
maintenance and growth. Micronutrients, including 
vitamins and minerals, are needed in very small 
quantities, but are nevertheless vital for the function 
of all cells, where they serve for example as 
hormones and co-factors for enzymes.   
 
There is tremendous variation between animal 
species in the composition of optimal diet. For 
example, some animals prefer high protein diet 
whereas some animals, such as hummingbirds, feed 
primarily on high-sugar content flower nectar. In 
contrast to dietary specialists, the flexible dietary 
generalists can survive on a wide range of diets. 
Human populations and individuals for instance 
show great variation in dietary behavior, also in the 
course of evolution. The modern human diet rich in 
carbohydrates and starch differs greatly from the 
typical diet of our ancestors, where the environment 
determined the diet of hunter-gatherers and fruits 
were the main source of dietary sugars (Perry et al. 
2007; Luca et al. 2010; Lustig et al. 2012). There is 
also great variation in the feeding behavior between 
modern human populations, and between 
individuals within populations. Despite the 
differences between diets, most humans still 
develop a similar body weight and composition. A 
crosstalk between highly complex nutrient sensing 
and downstream signaling pathways ensures the 
proper metabolic homeostasis under fluctuating 
nutritional conditions. 
 
Animals control their metabolic homeostasis by 
continuously integrating signals originating both 
from the body and environment. The endocrine 
system controls signaling between organs and 
nutrient partitioning into tissues. These signals can 
be nutritional, hormonal and neuronal, and they all 
carry information about the homeostatic status of a 
given macronutrient or its metabolite. The nutrient 
sensing mechanisms ensure the energy homeostasis 
of the body – the balance between catabolic and 
anabolic processes under fluctuating environmental 
and nutritional conditions. During fasting, the 
catabolic processes, such as the β-oxidation of fatty 
acids, provide an energy source for the cells to 
maintain essential functions. In turn, when nutrients 
are available, the anabolic processes that build up 
tissues and drive growth are activated. The 
mechanisms regulating the delicate balance of 
metabolic homeostasis are highly complex, and 
understanding the interplay between the nutrient 
sensing pathways is one of the central questions in 
physiology. 
 
Nutrient sensing is controlled both at the systemic 
and cellular level. At the systemic level, the organs 
involved in energy homeostasis integrate multiple 
inputs from the environment to control appropriate 
outputs. For example, after feeding, elevated blood 
glucose levels trigger the release of Insulin from the 
β-cells of pancreas, which in turn signals mainly to 
liver, adipose tissue and skeletal muscle to activate 
glucose uptake in order to maintain stable blood 
glucose levels (Roder et al. 2016). At the cellular 
level, glucose is sensed by an intracellular glucose 
sensor, namely ChREBP/MondoA-Mlx, that 
initiates a transcriptional response, which ensures 
that proper metabolic pathways are activated 
(Havula and Hietakangas 2012).  
1.1.1. Metabolic organs, tissues and digestion of 
macronutrients 
Key organs in whole-body energy homeostasis 
include the brain, digestive tract, pancreas, liver, 
adipose tissue and muscle. The digestive tract is the 
first organ to receive information from our external 
environment after feeding. The digestion of 
macronutrients begins in the mouth by mechanical 
digestion. Additionally, amylase, an enzyme 
secreted in the saliva, begins to break down starch. 
Protein digestion by pepsin starts in the stomach. 
The main site for digestion is the small intestine, 
where digestive enzymes secreted from the 
pancreas and bile from the liver ensure a proper 
breakdown of all macronutrients. Proteins are 
degraded into peptides and amino acids by 
proteases such as trypsin, and lipids are degraded 
into fatty acids and glycerol by lipases. Pancreatic 
amylase continues the digestion of starch into 
simple sugars. The small intestine produces and 
secretes the disaccharide digesting enzymes sucrase, 
lactase and maltase. Digested macronutrients are 
then absorbed through the small intestinal epithelial 
tissue into the blood vessels lining the intestinal 
tract. The undigested carbohydrates are also partly 
broken down by the intestinal bacteria of the colon. 
In addition to being in charge of the digestion and 
absorption of nutrients, the digestive tract also 
secretes hormones that signal to other organs of the 
nutrient state of the body. For example, Ghrelin 
secreted by  the  stomach and  small  intestine  is  a  
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signal of nutrient shortage, and Glucagon-like 
peptide 1 secreted by the intestine is a signal of 
nutrient arrival (Cummings and Overduin 2007). 
 
In addition to secreting most of the key digestive 
enzymes, the pancreas has a central role in 
regulating glucose homeostasis via the endocrine 
system by secreting multiple hormones. The 
counteracting hormones, Insulin and Glucagon, 
secreted by the β-cells and α-cells of pancreas, 
respectively, maintain blood glucose at a constant 
level (Roder et al. 2016) (Figure 1). During fasting, 
Glucagon both promotes hepatic glycogenolysis 
and gluconeogenesis to increase blood glucose 
levels. Insulin secretion is stimulated by feeding. 
After binding to its receptors in muscle and adipose 
tissue, it activates an intracellular signaling cascade 
that leads to the translocation of GLUT4 glucose 
transporters on the plasma membrane.  In addition, 
Insulin acts as an anabolic hormone by promoting 
glycogenesis, lipogenesis and protein synthesis 
(Biolo et al. 1995; Roder et al. 2016). The pancreas 
also secretes somatostatin, which inhibits Insulin 
and Glucagon secretion (Gerich et al. 1974; Hauge-
Evans et al. 2009).  
 
The liver has a central role in whole-body energy 
homeostasis.  Excess   dietary   carbohydrates    are  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
either stored as glycogen or transformed into lipids 
in the liver (Rui 2014). Glycogenesis, a process 
where glucose monomers are added into long 
glycogen polymers, is driven by Glycogenin and 
Glycogen synthase (Roach et al. 2012). In de novo 
lipogenesis (DNL), dietary carbohydrates are 
converted into fatty acids, which are further 
esterified with glycerol-3-phosphate to generate 
triacylglycerol (TAG). TAGs can be stored in the 
liver or they can be secreted from the hepatocytes 
as very low density lipoprotein (VLDL) particles 
and transported to other tissues, mainly adipose 
tissue, via the circulation (Rui 2014). DNL takes 
place mainly in the liver and to a lesser extent in the 
adipose tissue (Bjorntorp and Sjostrom 1978; 
Trayhurn 1981). DNL is promoted by feeding via 
two separate mechanisms. Increased Insulin 
signaling and increased intracellular glucose 
activate the Sterol regulatory element-binding 
protein (SREBP) and Carbohydrate-responsive 
element-binding protein (ChREBP), respectively, 
which activate the transcription of key lipogenic 
genes such as fatty acid synthase (FAS) and acetyl-
CoA carboxylase (ACC) (Dentin et al. 2004). Liver 
releases also many cytokines, collectively known as 
hepatokines. Key hepatokines include 
Angiopoietin-related protein 6 (ANGPTL6), 
Fibroblast growth factor 21 (FGF21) and Insulin-
Figure 1. Systemic regulation of glucose homeostasis by Insulin and Glucagon 
Glucose homeostasis is regulated at the systemic level by the counteracting hormones Insulin and Glucagon. When 
blood glucose levels rise, Insulin stimulates both the uptake of glucose in tissues and the formation of glycogen in the 
liver. When blood glucose levels fall, Glucagon stimulates the breakdown of glycogen to glucose. Modified from 
Benjamin Cummings, 2001. 
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like growth factors (IGFs), which signal to other 
organs and tissues about the metabolic state of the 
liver (Stefan and Haring 2013).  
 
Adipose tissue can be functionally divided into 
white, brown and to a more recently identified 
subclass, beige adipose tissue (Peirce et al. 2014). 
White adipose tissue (WAT) stores excess dietary 
calories in the form of triglycerides and is the main 
site of storage energy to be used by the body during 
fasting. WAT also communicates with other tissues 
and organs by secreting adipokines, such as 
adiponectin and Leptin (Scherer 2006). White fat 
cells, adipocytes, are morphologically 
characterized by a single large lipid vacuole that 
often fills almost the entire cell, leaving only a thin 
layer of cytoplasm surrounding it together with a 
nucleus. The main role of brown adipose tissue 
(BAT) is to generate heat in response to cold 
(Cypess et al. 2009; Virtanen et al. 2009). BAT also 
stores energy in the form of lipids, but unlike in 
WAT, the lipid droplets are small and spread 
around the cytoplasm. The main characteristic of 
BAT is the high abundance of mitochondria and 
high expression levels of uncoupling protein 1 
(UCP1 or thermogenin) (Cannon and Nedergaard 
2004). UCP1 is located at the inner mitochondrial 
membrane and it uncouples substrate oxidation 
from ATP production to produce heat (Cannon and 
Nedergaard 2004). Recently another UCP1 
expressing adipocyte cell type was identified. The 
beige or brite adipocytes, usually located within 
WAT, rise from WAT “browning” in response to 
cold exposure (Ishibashi and Seale 2010; Petrovic 
et al. 2010). Although both beige and brown 
adipocytes express high levels of UCP1, beige 
adipocytes have gene expression signature distinct 
from BAT (Wu et al. 2012). 
1.1.2. Control of food intake 
The hypothalamus controls feeding behavior via 
integrating neural, metabolic and hormonal signals, 
such as Leptin, Insulin, FGF21 and Ghrelin, which 
are secreted from the adipose tissue, pancreas, liver 
and stomach, respectively (Figure 2). Leptin is 
sensed by two distinct neuron types in the arcuate 
nucleus (ARC) of the 
hypothalamus. The Agouti-
related peptide (AgRP) and 
Neuropeptide Y (NPY) 
expressing neurons are inhibited 
by Leptin and stimulated by 
fasting, whereas the pro-
opiomelanocortin (POMC) 
expressing neurons are stimulated 
by Leptin and inhibited by fasting 
(Coll et al. 2007). Both 
AgRP/NPY and POMC neurons 
signal via Melanocortin 4 (MC4) 
receptors to control food intake 
and energy expenditure. Insulin 
has also been shown to act via the 
AgRP/NPY and POMC neurons 
to regulate peripheral glucose 
metabolism and food intake 
(Benoit et al. 2002; Konner et al. 
2007). FGF21 was recently 
described as the first liver-
derived hepatokine that acts in the 
brain to control feeding behavior. 
Sugar-feeding induces ChREBP-
dependent expression of FGF21 
in the liver, which signals to the 
paraventricular nucleus (PVN) in 
the hypothalamus to suppress 
carbohydrate intake (von 
Holstein-Rathlou et al. 2016).  
Figure 2. Control of food intake 
Hypothalamus in the brain controls feeding behavior by integrating hormonal 
signals from the body. Leptin is a satiety hormone released by adipose tissue. 
FGF21 is produced in the liver and it controls the intake of sugars. Insulin is 
secreted by the pancreas in response to elevated blood glucose levels and it 
reduces food intake. Ghrelin is secreted from the stomach when it is empty and 
it increases hunger. 
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1.1.3. Nutrient sensing pathways 
Ultimately, whole-body metabolism is regulated at 
the cellular level by specific nutrient sensors. Each 
nutrient is sensed separately by distinct 
mechanisms, which further activate downstream 
signaling pathways that in addition to directly 
activating metabolic enzymes, often include 
secondary effectors.  Nutrient sensing pathways 
activate the proper metabolic responses to each 
nutrient and also communicate with each other to 
ensure metabolic homeostasis (Figure 3). 
 
Nutrients are metabolized by metabolic enzymes, 
which are regulated both over short term and long 
term periods. In the short term, the regulation is 
mainly allosteric and involves post-translational 
mechanisms, such as phosphorylation or O-
GlcNAcylation. In the long term, metabolic 
enzymes are usually regulated at the transcriptional 
level. Key transcriptional regulators of metabolic 
enzymes include SREBP, ChREBP, MondoA, USF, 
LXR, FXR, RXR, PPAR, HNF4α, STAT3, CREB 
and FOXO1 (Table 1). Transcription factors can act 
directly as nutrient sensors or can be activated by 
upstream sensors. An understanding of the highly 
complex crosstalk between nutrient sensing 
pathways is only about to emerge, and new nutrient 
sensors are being constantly described. 
1.1.3.1. Amino acid sensing  
Proteins are composed of amino acids that can be 
further divided into essential and non-essential 
amino acids. The non-essential amino acids, alanine, 
asparagine, aspartic acid, arginine, cysteine, 
glutamine, glycine, glutamic acid, serine, proline 
and tyrosine can be synthesized by the body, 
whereas the other nine amino acids, leucine, 
isoleucine, lysine, histidine, methionine, 
phenylalanine, threonine, tryptophan and valine, 
are required in the human diet. During protein 
synthesis, amino acids are incorporated into 
polypeptide chains at the ribosome by transfer 
RNAs (tRNAs). Any uncharged tRNAs are 
recognized by a protein called General control 
nonderepressible (GCN2), which upon activation 
triggers   the   phosphorylation   and   inhibition  of           
Figure 3. Intracellular nutrient-sensing pathways 
Abbreviations: AKT: Protein kinase B, AMP: Adenosine monophosphate, AMPK: AMP-activated protein kinase, G6P: 
Glucose-6-phosphate, HK: Hexokinase, IRS: Insulin receptor substrate, LXR: Liver X receptor, MAP4K3: Mitogen-
activated protein kinase kinase kinase kinase 3, PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase, PPAR: 
Peroxisome proliferator-activated receptor, RXR: Retinoid X receptor, TOR: Target of rapamycin, TORC1: TOR 
complex 1, SREBP: Sterol regulatory element-binding protein, Vps34: Vacuolar protein sorting 34 
(Phosphatidylinositol 3-kinase catalytic subunit type 3, PIK3C3) 
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eukaryotic translation initiator factor 2 α (eIF2α) 
(Berlanga et al. 1999; Dong et al. 2000). GCN2 
could be therefore considered an intracellular 
amino acid sensor.  
 
There is no specific definition of a nutrient sensor. 
Broad definitions that include a wide variety of 
nutrient recognizing molecules such as taste 
receptors have been suggested (Miyamoto et al. 
2013). Taste receptors indeed activate signaling 
cascades leading all the way to the hypothalamus to 
control our feeding behavior. In the following I will 
however focus on those key molecules that 
recognize their specific substrates shortly after they 
are taken into the cells, and regulate metabolic 
target genes and signaling cascades to adjust whole-
body metabolism to nutritional input.  
 
Target of rapamycin (TOR) is perhaps the most 
extensively studied nutrient sensor. Although TOR 
is not a direct amino acid sensor, it plays an 
indisputable role in amino acid sensing and its 
activity is regulated by amino acid levels. However, 
the exact mechanisms of amino acid sensing are 
only becoming elucidated. TOR was originally 
identified as a gene that provides resistance to the 
antifungal drug called rapamycin (Heitman et al. 
1991). It is a serine/threonine kinase and a member 
of the Phosphoinositide 3-kinase (PI3K)-related 
kinase family and acts as the catalytic subunit of 
two distinct complexes composed of different sets 
of proteins, and distinct upstream regulators and 
downstream functions (Laplante and Sabatini 2012). 
TOR complex 1 (TORC1) and 2 are both composed 
of TOR, Mammalian lethal with SEC13 protein 8 
(MLST8) and the non-core components, but differ 
by key scaffold proteins that also define the 
mechanisms by which the complexes control 
growth. In TORC1, the binding partner of TOR is 
the Regulatory-associated protein of TOR 
(RAPTOR), and in TORC2, the Rapamycin-
insensitive companion of TOR (RICTOR) 
(Laplante and Sabatini 2012). As the name of 
RICTOR states, TORC2 is insensitive to rapamycin. 
According to current knowledge, TORC2 is 
regulated by growth factors but not amino acids. It 
regulates survival, metabolism and cytoskeletal 
organization, however, information on TORC2 is 
still limited (Gaubitz et al. 2016).  
 
TORC1 regulates growth by integrating 
information about nutritional status and growth 
signals to control a wide variety of cellular 
biosynthetic processes such as ribosome biogenesis 
and protein synthesis via its downstream targets, 
including S6 kinase (S6K) and Eukaryotic initiation 
factor 4E binding protein (4E-BP) (Holz et al. 2005; 
Tee and Blenis 2005; Ma and Blenis 2009). Other 
functions of TORC1 include control of lipid 
biosynthesis via S6K and SREBP, and glycolysis 
via Hypoxia-inducible factor 1α (HIF1α) (Duvel et 
al. 2010; Li et al. 2011). TORC1 also inhibits 
autophagy by phosphorylating and thus suppressing 
the kinase complex required for the initiation of 
autophagy (Ganley et al. 2009; Hosokawa et al. 
2009; Jung et al. 2009). In the absence of amino 
acids, especially leucine and arginine, TORC1 is 
not activated (Blommaart et al. 1995; Hara et al. 
1998).  
 
The amino acid dependent activation of TORC1 
takes place at lysosomes and is mediated by Rag 
GTPases that bind RAPTOR (Kim et al. 2008a; 
Sancak et al. 2008). The regulation of TORC1 
activity is complex and involves a number kinases, 
including AMPK-activated protein kinase (AMPK), 
PI3K and AKT (Protein kinase B), which however 
regulate TORC1 in response to signals other than 
amino acids, including Insulin and Glycogen 
(Hietakangas and Cohen 2009). The Mitogen-
activated protein kinase kinase kinase kinase 3 
(MAP4K3) and the class III PI3K VPS34 (Vacuolar 
protein sorting 34) in turn have been linked to the 
amino acid sensing function of TORC1. MAP4K3 
is activated by amino acids and it physically 
interacts with Rag GTPases (Bryk et al. 2010). 
VPS34 has been shown to be required for the amino 
acid dependent activation of TORC1 (Byfield et al. 
2005).  
 
In addition, a number of cytosolic proteins, such as 
Folliculin (FLCN)/FLCN-interacting protein and 
GATOR-proteins, have been recently suggested to 
provide a link between amino acid sensing, 
modulation of Rag GTPases and TORC1 (Tsun et 
al. 2013; Shimobayashi and Hall 2016). Most 
recently, leucine was shown to directly bind Sestrin 
2, leading to disruption of Sestrin 2-GATOR2 
interaction and to TORC1 activation 
(Chantranupong et al. 2014; Saxton et al. 2016b; 
Wolfson et al. 2016). Arginine, another potent 
activator of TORC1, was also recently shown to be 
directly bound by CASTOR1, another GATOR2 
interacting protein (Chantranupong et al. 2016; 
Saxton et al. 2016a) (Figure 3). 
 
Amino acids enter the cell via amino acid 
transporters, which have been proposed to serve as 
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amino acid sensors and regulators of TORC1 
activity (Goberdhan et al. 2016). However, TORC1 
signaling is also active in the absence of 
extracellular amino acids, suggesting that 
intracellular amino acid pools or biosynthesis are 
sufficient to activate TORC1, and that the amino 
acid sensing takes place inside the cell (Sancak et 
al. 2008). Increasing evidence suggests that 
different amino acids are sensed in different 
compartments of the cell, and that TORC1 responds 
to different upstream signals and activates distinct 
downstream effector pathways (Goberdhan et al. 
2016). 
1.1.3.2. Lipid sensing 
There are thousands of different types of lipids in 
mammals, but they can be roughly categorized into 
six groups: fatty acids, glycerolipids (triglycerides), 
(glycerol)phospholipids, sphingolipids, sterol lipids 
and prenol lipids (LIPID MAPS classification). 
Glycerolipids, or triglycerides, are formed by the 
esterification of glycerols with different fatty acids, 
and serve as a main storage form of fat in animals.  
Phospholipids form lipid bilayers due to their 
hydrophobic fatty acid tails and hydrophilic 
phosphate head groups, and are the major 
component of cell membranes. Sphingolipids, 
including ceramides, sphingomyelins and 
glycosphingolipids, are structurally more complex 
lipids. They are found in the plasma membrane but 
have also an important role as signaling molecules. 
Cholesterol, the most well-known sterol, is an 
abundant component of cell membranes, but acts 
also as a precursor for the synthesis for steroid 
hormones.  
 
Lipid sensing nuclear receptors include the 
Peroxisome proliferator-activated receptors 
(PPARs), their co-activator PPARγ co-activator 1α 
(PGC1α), Liver X receptor (LXR) and Hepatocyte 
nuclear factor 4α (HNF4α). PPARs are 
transcription factors that are activated by fatty acids 
(Christodoulides and Vidal-Puig 2010). Different 
PPAR subtypes (PPARα, -β/δ and -γ) regulate 
different processes. PPARα is activated during 
starvation, and it regulates gluconeogenesis, lipid 
trafficking and inhibition of DNL (Atherton et al. 
2009; Vacca et al. 2015).  PPARγ in turn promotes 
adipogenesis, lipid storage, fatty acid and  glucose 
uptake (Lehrke and Lazar 2005). LXRs are 
activated by oxysterols and act as heterodimers 
with Retinoid X receptors (RXRs) to control 
lipogenesis and cholesterol synthesis (Janowski et 
al. 1996; Calkin and Tontonoz 2012). HNF4α 
regulates glucose, fatty acid and cholesterol 
metabolism (Jiang et al. 1995; Odom et al. 2004; 
Martinez-Jimenez et al. 2010). HNF4α binds 
linoleic acid, however the functional role for 
linoleic acid binding is still not clear, since the 
binding does not have a significant effect on the 
transcriptional activity of HNF4α (Yuan et al. 
2009). HNF4α and PPARs regulate each other’s 
expression and thereby coordinate their functions 
(Martinez-Jimenez et al. 2010). Fatty acids are also 
sensed by the G-protein-coupled receptors GPR40 
and GPR120, which upon activation, stimulate 
glucose uptake (Itoh et al. 2003; Oh et al. 2010).  
 
Intracellular cholesterol sensing is a well-
characterized process involving SREBP proteins 
and SREBP cleavage-activating protein (SCAP), 
which are bound as a complex to the endoplasmic 
reticulum (ER). When cholesterol is abundant, 
SCAP binds cholesterol and the complex remains 
anchored in the endoplasmic reticulum (ER) 
(Brown et al. 2002; Yang et al. 2002). When 
cholesterol levels are low, the SREBP-SCAP 
complex dissociates from the ER and shuttles to the 
Golgi where SREBP is cleaved and the amino 
terminal transcription factor domain translocates to 
the nucleus and activates the transcription of genes 
involved in cholesterol synthesis (Radhakrishnan et 
al. 2008; Motamed et al. 2011; Jeon and Osborne 
2012). The regulation and functions of SREBPs are 
discussed in more detail in Chapter 1.3.2. 
1.1.3.3. Carbohydrate sensing 
Dietary carbohydrates include sugars, starches and 
fibers. Digestive enzymes break down starch and 
sugars (disaccharides) into simple sugars that can 
be absorbed through the small intestine into the 
circulation. Blood glucose levels are maintained in 
a very narrow range by the counteracting hormones 
Insulin and Glucagon. The β-cells of pancreas 
express and secrete Insulin in response to elevated 
blood glucose levels and increased glucose 
metabolism (Poitout et al. 2006). The binding of 
Insulin to Insulin receptors (IR) induces an 
intracellular signaling cascade, which leads to an 
enrichment of insulin sensitive Glucose 
transporters (GLUT4) on the plasma membrane and 
glucose uptake (James et al. 1988; Furtado et al. 
2002). When blood glucose levels fall, the α-cells 
of pancreas release Glucagon, which stimulates 
glycogenolysis, the breakdown of glycogen into 
glucose molecules that are released into the 
bloodstream (Wasserman et al. 1989). 
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Sugars are transported into the cells via sugar 
transporters. The GLUT (Solute carrier family 2, 
SLC2) family of glucose transporters includes 14 
members belonging to the Major facilitator 
superfamily (MFS) of membrane transporters, from 
which the GLUTs 1-4 are the best characterized 
(Thorens and Mueckler 2010; Mueckler and 
Thorens 2013). GLUT1 and 3 are mainly expressed 
in fetal tissues and adult brain (Simpson et al. 1994; 
Shin et al. 1997; Simpson et al. 2008). GLUT1 was 
the first glucose transporter to be characterized, and 
it is also the main glucose transporter of red blood 
cells (Mueckler et al. 1985). The insulin responsive 
GLUT4 is most highly expressed in adipose tissue, 
skeletal and cardiac muscle (James et al. 1988; 
James et al. 1989). The expression of GLUT2 is 
highest in hepatocytes and pancreatic β-cells, and 
unlike other GLUTs, it has a low affinity for 
glucose (Thorens 1992) .  
 
When glucose is taken into the cell, it is readily 
phosphorylated into glucose-6-phosphate (G6P) by 
hexokinases. The mammalian hexokinases I-III 
have a high affinity for glucose and they are all 
inhibited by G6P, whereas the type IV, commonly 
referred to as “glucokinase”, has a very low affinity 
to glucose (Wilson 2003). Despite its name, 
glucokinase can also phosphorylate hexoses other 
than glucose, similarly to other hexokinases 
(Cardenas et al. 1998). Glucokinase is only active 
when glucose levels rise above a certain threshold 
(half-saturated at 8 mmol/L) and it is expressed at 
high levels in the liver and pancreas. Glucokinase 
is thus considered as a systemic glucose sensor that 
controls circulating glucose levels by promoting 
Insulin release from the pancreas and glycogenesis 
in the liver, only when the blood glucose levels 
reach a threshold level (Postic et al. 2001; 
Matschinsky 2002; Iynedjian 2009). Glucokinase 
and GLUT2 share the same expression pattern and 
low affinity for glucose. Together they form a 
glucose sensor that promotes glucose import and 
metabolism in pancreas followed by release of 
Insulin during hyperglycemia, whereas low blood 
glucose levels lead to liver GLUT2-mediated 
export of glucose originating from hepatic 
glycogenolysis and gluconeogenesis.  
 
In addition to systemic glucose sensing, glucose 
and energy levels are sensed by intracellular 
mechanisms. AMPK is activated by increased 
cellular levels of AMP and ADP and it serves as a 
regulatory switch between catabolic and anabolic 
pathways depending on cellular energy status 
(Hardie et al. 2012). AMPK phosphorylates and 
inhibits the activity of lipogenic genes SREBP and 
ACC. In response to low energy levels, it also 
inhibits TORC1 and protein synthesis via 
phosphorylation of RAPTOR and Tuberous 
sclerosis complex 2 (TSC2) (Inoki et al. 2002; 
Gwinn et al. 2008).  
 
The true sugar sensor, Carbohydrate response 
element binding protein (ChREBP), was 
discovered in 2001 by the laboratory of Kosaku 
Uyeda. This study followed the work of Howard 
Towle’s lab, which had identified the carbohydrate 
response element (ChoRE) as a motif mediating the 
expression of hepatic genes in response to glucose 
(Thompson and Towle 1991; Shih and Towle 1992; 
Shih and Towle 1994; Shih et al. 1995). The Uyeda 
group studied the mechanism by which glycolytic 
and lipogenic genes were transcriptionally induced 
in response to elevated carbohydrate levels, and 
were able to purify the ChREBP transcription factor 
from the promoter of the rat L-type pyruvate kinase 
(LPK) gene (Yamashita et al. 2001). ChREBP had 
been actually already found some years before as a 
new binding partner for Mlx, the recently identified 
novel member in the Myc-network of transcription 
factors (Billin et al. 2000; Meroni et al. 2000). The 
same study identified two Mondo paralogues, 
MondoA and MondoB (MondoB was named 
ChREBP by Yamashita et al.) (Billin et al. 2000). 
Since their discovery, the regulation and functions 
of ChREBP/MondoA-Mlx transcription factors 
have been studied extensively, which is also the 
focus of this thesis. 
1.2. Carbohydrate Response Element Binding 
Protein ChREBP, MondoA and Mlx 
1.2.1. ChREBP, MondoA and Mlx belong to the 
bHLH/LZ family of transcription factors 
The basic helix-loop-helix/leucine zipper 
(bHLH/LZ) class of transcription factors is a large 
family of transcription factors. They belong to the 
bHLH superfamily and are characterized by an 
additional leucine zipper domain that mediates 
dimerization in addition to the HLH domain. All 
bHLH proteins recognize and bind specific 
hexanucleotide sequences (5’-CANNTG-3’) 
known as Enhancer box (E-box) (Massari and 
Murre 2000). The basic domain mediates binding to 
the E-box, and the consensus E-box sequence varies 
between different bHLH families. The E-box motif 
recognized specifically by ChREBP/MondoA-Mlx 
is called the carbohydrate response element 
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(ChoRE) and it is composed of two E-box elements 
spaced by 5 nucleotides, to which 
ChREBP/MondoA-Mlx bind as heterotetramers 
(Figure 4) (Shih et al. 1995; Ma et al. 2006). Other 
members of the bHLH/LZ transcription factors 
include SREBPs and the Myc-family. SREBPs 
recognize a modified type of E-box named sterol 
regulatory element (SRE) (TCACNCCAC), and 
they regulate cholesterol and fatty acid biosynthesis 
(Yokoyama et al. 1993; Kim et al. 1995; Brown and 
Goldstein 1997).  
 
Myc is one of the most extensively studied 
transcription factors. The Myc-family is composed 
of 5 members. The first one, c-Myc, was originally 
identified in Burkitt lymphoma patients as a cellular 
homologue to the viral oncogene found in the avian 
myelocytomatosis retrovirus (v-Myc) (Vennstrom 
et al. 1982). Myc is also a well-known proto-
oncogene mutated in many human cancers (Dang 
2012). Myc works together with its binding partner 
Max to activate the transcription of a great number 
of target genes that regulate proliferation, apoptosis 
and metabolism (Blackwell et al. 1990; Blackwood 
and Eisenman 1991; Amati et al. 1993a; Amati et 
al. 1993b; Dang 1999; Prendergast 1999). 
Heterodimerization with Max is required for Myc 
to activate transcription. The Mad-family members 
compete with Myc for binding to Max, but in 
contrast to Myc, the Mad-Max heterodimers act as 
transcriptional repressors, thus antagonizing the 
function of Myc-Max (Ayer et al. 1993; Grandori et 
al. 2000) (Figure 5). Myc-family members also 
contain the bHLH/LZ domain and they bind single 
E-boxes together with their dimerization partner 
Max (Blackwood and Eisenman 1991; Kretzner et 
al. 1992; Amati et al. 1993a).  
 
Another specialized class of bHLH proteins is the 
family of bHLH-O TFs that are characterized by an 
Orange domain. The function of the Orange domain 
is not completely understood, but it has been 
suggested to mediate specificity, transcriptional 
repression and also dimerization (Steidl et al. 2000; 
Davis and Turner 2001). Based on their structure, 
the bHLH-O family is further divided into Hes, Hey, 
Helt and Stra13/Dec subfamilies (Sun et al. 2007). 
bHLH-O TFs act as transcriptional repressors and 
regulate a wide variety developmental processes by 
modulating Notch signaling (Artavanis-Tsakonas 
et al. 1999; Davis and Turner 2001). The Stra/Dec 
subfamily members are known regulators of 
circadian rhythm (Honma et al. 2002), but have also 
been shown to have roles in peripheral tissues, for 
example as regulators of lipid metabolism, in 
response to hypoxia (Yun et al. 2002; Choi et al. 
2008). Stra13/Dec proteins bind to tandem E-box 
elements as homodimers and act as transcriptional 
repressors in a histone deacetylase (HDAC)-
dependent manner (Fujimoto et al. 2007). 
1.2.2. Myc-Max-Mad-Mlx-Mondo transcription 
factor network 
Early studies on the Mondo-network involved 
identification of MondoA and MondoB (ChREBP) 
as proteins able to bind Mlx (Max-like protein X), 
which in turn had been previously identified as a 
new bHLH/LZ protein interacting with Mad1 and 4 
in vitro (Billin et al. 1999; Billin et al. 2000; Meroni 
et al. 2000). MondoB was also independently 
identified in humans as a gene deleted in Williams-
Beuren syndrome (called as WBSCR14; Williams-
Beuren syndrome critical region gene 14) (de Luis 
et al. 2000; Cairo et al. 2001).  
 
The most important clue of the molecular function 
of Mondo-proteins came from a study that 
identified ChREBP as the glucose-activated 
transcription factor regulating the L-type pyruvate 
kinase (L-PK) gene by binding to its promoter via 
the ChoRE (Yamashita et al. 2001). The 
carbohydrate response element in L-PK promoter 
had been identified previously, but its regulation 
had remained elusive (Thompson and Towle 1991). 
The identification of ChREBP as the carbohydrate 
responsive transcription factor was followed by the 
demonstration of functionally essential 
heterodimerization with Mlx in the context of 
glucose sensing, as well as the glucose 
responsiveness of the ChREBP orthologue 
Figure 4. ChREBP/MondoA-Mlx recognize and bind 
ChoREs  
The consensus sequence of a carbohydrate response 
element (ChoRE). ChREBP/Mlx and MondoA/Mlx 
recognize and bind ChoREs, which are composed of two 
E-box elements spaced by 5 nucleotides. Modified from 
Poungvarin et al. 2015.  
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MondoA (Stoeckman et al. 2004; Li et al. 2006; 
Stoltzman et al. 2008). The functional 
characterization of ChREBP led to the adaptation 
of the name over MondoB. 
 
Although Mlx has been shown to be able to bind 
also some of the Mad-family members in an in vitro 
setting, the in vivo function of Mad-Mlx 
heterodimers remains to be established. (Billin et al. 
1999; Meroni et al. 2000). However, several studies 
have indicated that Mlx does not bind to Myc-
family members and that Mondo proteins do not 
bind to Max (Billin et al. 1999; Meroni et al. 2000; 
Cairo et al. 2001), thus implying that the Mlx-
Mondo network forms an independent side branch 
to the Myc-Max-Mad-Mlx-Mondo network of 
bHLH/LZ transcription factors (Figure 5). 
1.2.3. Mondo proteins are highly conserved  
MondoA (human gene MLXIP) and ChREBP 
(MLXIPL) are located on different chromosomes 
(12q21.31 and 7q11.23 in human, respectively). 
They both regulate glucose-induced transcription, 
but in a tissue specific manner: ChREBP is 
predominantly expressed in the liver, adipose tissue 
and pancreas, whereas MondoA function is most 
important in the skeletal muscle (Billin et al. 2000; 
Yamashita et al. 2001; Wang and Wollheim 2002; 
He et al. 2004; Iizuka et al. 2004; Dentin et al. 2006). 
MondoA and ChREBP 
share many target genes, 
suggesting a possible 
functional redundancy 
between the paralogues, 
but there also appears to 
be major differences, 
reflecting for example 
the site of action.  
 
Mondo and Mlx 
proteins are highly 
conserved in evolution. 
The vertebrate genome 
encodes two Mondo 
proteins, MondoA and 
ChREBP. Furthermore, 
in mammals the 
ChREBP gene encodes 
two isoforms, ChREBP-
α and ChREBP-β, 
which are transcribed 
from different 
promoters (Herman et al. 
2012). ChREBP-α is 
activated by glucose and it stimulates the 
expression of ChREBP-β, which has 20-fold higher 
transcriptional activity when compared to 
ChREBP-α (Herman et al. 2012). The ChREBP-β 
isoform is found in mammals, birds, reptiles and 
amphibians but is absent in fish, indicating that the 
novel isoform developed during the divergence of 
the tetrapod lineage (Singh and Irwin 2016). The 
same study also found that MondoA has changed 
less during evolution compared to ChREBP, 
suggesting a more ancient and strictly controlled 
role for MondoA in regulating metabolism, namely 
glycolysis (Singh and Irwin 2016).  
 
The Drosophila genome contains a single Mondo 
(Mio, CG18362) and an Mlx (Bigmax, CG3350) 
gene along with single orthologues for Myc, Max 
and Mad (Gallant et al. 1996; Peyrefitte et al. 2001; 
McFerrin and Atchley 2011) (Figure 5). In 
Caenorhabditis elegans, the network is markedly 
different and composed of a single Mlx orthologue 
Mxl-2, two Max orthologues Mxl-1 and Mxl-3, and 
a common orthologue for Myc and Mondo, called 
Myc and Mondo like-1 (Mml-1) (Billin and Ayer 
2006; Pickett et al. 2007; McFerrin and Atchley 
2011).  
 
The origin of the Max and Mlx network has been 
estimated to precede the origin of animals (over 500 
Figure 5. The Myc-Max-Mad-Mlx-Mondo network 
The vertebrate and Drosophila Myc-Max-Mad-Mlx-Mondo networks. Myc, when bound 
to Max, is a transcriptional activator. Max is also bound by the Mad-family members, 
which leads to transcriptional repression. Mlx has been identified as an interactor for Mnt, 
Mad4 and Mad1 in vitro. Mlx is the obligate binding partner of ChREBP and MondoA 
for transcriptional activation. The Drosophila genome encodes a minimal Myc-Max-
Mad-Mlx-Mondo network with only one paralogue for each member of the network.  
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Ma), and members of the network have been 
identified basically in all multicellular animals 
(McFerrin and Atchley 2011). Genome and gene 
duplication events during vertebrate evolution have 
probably resulted in the radiation of Myc, Mxd 
(Max, Mlx and Mnt) and Mondo proteins. However, 
whereas there are multiple copies of Myc, Mad and 
Mondo, only single copy of Max, Mlx and Mnt 
exists in vertebrates, suggesting that they have been 
under strong selection during evolution.  
1.2.4. Glucose-6-phosphate regulates the activity 
of ChREBP/MondoA  
Since their identification, ChREBP/MondoA-Mlx 
have been established to be nutrient regulated 
transcription factors. Their activity is induced by 
sugars and suppressed by polyunsaturated fatty 
acids (PUFAs) (Dentin et al. 2004; Dentin et al. 
2005a; Meng et al. 2016). Although the exact 
mechanism how sugars activate 
ChREBP/MondoA-Mlx is still under investigation, 
several lines of evidence suggest that ChREBP and 
MondoA sense and bind glucose-derived 
intermediates directly. Whereas the first studies 
pointed to the direction of xylulose-5-phosphate 
(Xu-5P) (Kabashima et al. 2003), the intermediate 
of the pentose phosphate pathway, a large number 
of subsequent studies have shown that ChREBP 
and MondoA are activated by glucose-6-phosphate 
(G6P) (Stoltzman et al. 2008; Li et al. 2010a; 
Dentin et al. 2012). Recent studies have also 
suggested that MondoA-Mlx can sense and be 
activated by other phosphorylated hexoses as well, 
including glucosamine (Stoltzman et al. 2011). 
Furthermore, it has been shown that fructose 2,6-
bisphosphate is required for the recruitment of 
ChREBP-Mlx to the promoters of selected set of 
target genes, suggesting that the activity of 
ChREBP-Mlx is also fine-tuned by metabolites 
other than G6P (Arden et al. 2012).   
 
ChREBP and MondoA are large multidomain 
proteins (~ 900 amino acids) (Figure 6). The C-
terminal bHLH/LZ domain mediates DNA binding 
and heterodimerization with Mlx. The 
transcriptional activation domain is supplied by the 
Mondo proteins, whereas the much shorter Mlx 
lacks the transactivation capacity and is considered 
an always abundant passive partner of the complex 
(Billin et al. 1999; Billin et al. 2000; Meroni et al. 
2000; Stoeckman et al. 2004). The C-terminus of 
MondoA, ChREBP and Mlx also contains an 
additional cytoplasmic and dimerization domain 
(CDC), which mediates both the cytoplasmic 
localization activity and interaction between 
ChREBP/MondoA and Mlx (Cairo et al. 2001; 
Eilers et al. 2002).   
 
The N-terminal region of ChREBP/MondoA 
contains the glucose-sensing module (GSM), which 
is responsible for the glucose responsiveness of 
ChREBP and MondoA. The glucose-sensing 
Figure 6. The domain structure of ChREBP/MondoA and Mlx 
ChREBP, MondoA and Mlx are multidomain proteins. The homologous C-terminal regions contain the dimerization 
and cytoplasmic localization domain (DCD) and basic helix-loop-helix leucine zipper region (bHLH/LZ), which 
mediate their heterodimerization and DNA binding. The glucose sensing module in the N-terminus of ChREBP and 
MondoA, contains the low-glucose inhibitory domain (LID) and the glucose-response activation conserved element 
(GRACE), which mediate the glucose-responsiveness of ChREBP/MondoA. The N-terminal region has been also 
divided into five functional subdomains called Mondo conserved regions (MCR). MCRI-IV corresponds to LID and 
GRACE contains the MCRV. The subcellular localization of ChREBP/MondoA-Mlx is controlled by a number of 
proteins. CRM1 (Exportin 1) binds the nuclear export sequences NES1 and NES2. 14-3-3 binding site is located in 
MCRIII. The nuclear localization signal in MCRIV is bound by Importin-α. Modified from Havula & Hietakangas, 
2012. 
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function of GSM is highly conserved – replacing 
the GSM of ChREBP with MondoA GSM retains 
the glucose responsiveness of the molecule (Li et al. 
2006). The GSM, also known as the Mondo 
conserved region (MCR), is functionally divided 
into low-glucose inhibitory domain (LID) and 
glucose response activation conserved element 
(GRACE), which roughly respond to MCRI-IV and 
MCRV regions, respectively (Eilers et al. 2002; Li 
et al. 2006). Under low glucose conditions, the LID 
domain inhibits GRACE (Li et al. 2006). When 
glucose levels rise, the repression of GRACE by 
LID is relieved. The current models suggest that a 
direct binding of G6P to LID leads to a 
conformational change, thus allowing the 
interaction with Mlx and other coactivators (Davies 
et al. 2010; McFerrin and Atchley 2011). This 
model, where LID acts as a glucose signal 
mediating inhibitory domain, is supported by the 
notion that a LID-deletion form of ChREBP is 
highly active also under low glucose conditions 
(Davies et al. 2010). Moreover, the recently 
identified novel ChREBP-β isoform lacks the LID 
domain and its transcriptional activity is not 
dependent on glucose levels (Herman et al. 2012). 
1.2.5. Regulation of ChREBP activity by 
posttranslational modifications and protein 
interactions 
ChREBP and MondoA shuttle between the cytosol 
and nucleus both under low and high glucose 
concentrations, however the nuclear entry rate is 
increased by high glucose levels (Kawaguchi et al. 
2001; Davies et al. 2008; Peterson et al. 2010) 
(Figure 7). Heterodimerization between 
ChREBP/MondoA and Mlx is required for the 
binding to ChoREs, transcriptional activity and 
nuclear entry (Eilers et al. 2002; Stoeckman et al. 
2004; Ma et al. 2007; Davies et al. 2008; Stoltzman 
et al. 2008; Peterson et al. 2010). Moreover, 
MondoA-Mlx has been shown to shuttle between 
nucleus and mitochondria in the cytoplasm, where 
it physically interacts with the outer mitochondrial 
membrane (OMM) (Sans et al. 2006; Stoltzman et 
al. 2008). This type of retrograde communication 
between mitochondria and nucleus has been 
suggested to serve as a sensory mechanism for the 
cellular energy status (Sans et al. 2006). Although 
physical interaction between ChREBP and 
mitochondria has not been demonstrated, its 
localization in hepatocytes resembles the 
punctuated cytoplasmic localization typical for 
mitochondria (Kawaguchi et al. 2001). 
 
Although the primary mode of ChREBP/MondoA-
Mlx regulation seems to take place by the 
cytoplasmic-nuclear localization induced by 
glucose, nuclear localization alone is not sufficient 
for the transcriptional activation of 
ChREBP/MondoA-Mlx (Davies et al. 2008; 
Peterson et al. 2010), and additional regulatory 
steps are required for target gene activation. In the 
cytoplasm, the activity of ChREBP/MondoA-Mlx 
is regulated by multiple post-translational 
modifications as well as by interactions with other 
proteins.  The N-terminus of ChREBP/MondoA 
contains a nuclear localization signal (NLS) and 
two nuclear export signals (NES1 and NES2) (de 
Luis et al. 2000; Eilers et al. 2002; Fukasawa et al. 
2010; Ge et al. 2011). Also, the interaction between 
ChREBP and 14-3-3 has been shown to regulate the 
subcellular localization of ChREBP and MondoA 
(Eilers et al. 2002; Merla et al. 2004; Li et al. 2008; 
Sakiyama et al. 2008) (Figure 7). 
 
Regulation of ChREBP activity via cAMP 
dependent protein kinase A (PKA) and AMPK 
mediated phosphorylation has been under extensive 
investigation, however none of the identified 
phosphorylation sites have been exclusively shown 
to be required for ChREBP activation or inhibition 
(Kawaguchi et al. 2001; Kawaguchi et al. 2002; Li 
et al. 2006; Tsatsos and Towle 2006; Denechaud et 
al. 2008a; Tsatsos et al. 2008).  However, a 
simultaneous mutation of multiple phosphorylation 
sites within LID leads to the inhibition of glucose-
responsiveness, suggesting that regulation of 
ChREBP/MondoA activity by phosphorylation 
involves a complex interplay between multiple 
phosphorylation sites (Tsatsos et al. 2008).  
 
In addition to phosphorylation, ChREBP is also 
modified by acetylation and O-GlcNAcylation 
(Bricambert et al. 2010; Sakiyama et al. 2010; 
Guinez et al. 2011). Histone acetyltransferase 
(HAT) coactivator recruitment takes place before 
the transcriptional activation of both ChREBP and 
MondoA (Cha-Molstad et al. 2009; Peterson et al. 
2010). The transcriptional coactivator p300 
interacts and acetylates ChREBP, thereby 
promoting DNA binding of the complex 
(Bricambert et al. 2010). p300 activity in turn is 
inhibited by Salt-inducible kinase 2 (SIK2), the 
activity of which is regulated by nutritional signals 
such as starvation (Du et al. 2008; Bricambert et al. 
2010). O-GlcNAcylation both stabilizes ChREBP 
protein and increases its transcriptional activity 
(Guinez et al. 2011) (Figure 7). To conclude, the 
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regulation of ChREBP/MondoA-Mlx activity 
seems to be a complex interplay between 
posttranslational modifications and a coordinated 
action of regulatory proteins that control both the 
nuclear entry and transcriptional activity of the 
complex in response to nutritional signals.  
1.2.6. Transcriptional regulation of 
ChREBP/MondoA-Mlx 
In addition to posttranslational modifications, 
ChREBP, MondoA and Mlx are also regulated at 
the transcriptional level. Posttranslational 
Figure 7. Regulation of ChREBP/MondoA-Mlx activity 
Abbreviations: Ac: Acetylation, AMP: Adenosine monophosphate, AMPK: AMP-activated protein kinase, ChoRE: 
Carbohydrate response element, CRM1: Chromosome region maintenance 1 (Exportin 1), Fru-2,6-P2: Fructose 2,6-
bisphosphate, G6P: Glucose-6-phosphate, HKII: Hexokinase II, HKIV: Hexokinase IV (Glucokinase), O-GlcNAc/O-
G: O-linked β-N-acetylglucosamine, PKA: Protein kinase A, PUFA: Polyunsaturated fatty acids, SIK2: Salt inducible 
kinase 2 
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mechanisms are in charge of the rapid, nutrient-
triggered regulation of ChREBP/MondoA-Mlx 
activity. However, it has become evident, 
especially after identification of the ChREBP-β 
isoform, that transcriptional regulation plays an 
important role in the long term regulation of 
ChREBP/MondoA-Mlx activity. ChREBP 
expression is induced in the liver, especially after 
high carbohydrate feeding (Dentin et al. 2004; 
Meng et al. 2016). ChREBP transcript levels are 
also increased by Insulin via the Octamer 
transcription factor-1 (Oct-1), which has been 
shown to bind ChREBP promoter after Insulin 
stimulation (He et al. 2004; Sirek et al. 2009).  
 
The interrelationship between nuclear factors and 
ChREBP is perhaps the most extensively studied 
field of transcriptional regulation of ChREBP 
(Poupeau and Postic 2011). Nuclear receptors, 
including PPARs, LXR and HNF-4α,  are 
transcription factors that are activated by ligands, 
such as hormones and a variety of small molecules 
(Robinson-Rechavi et al. 2003; Evans and 
Mangelsdorf 2014). The ligand binding can take 
place in the cytoplasm, followed by a translocation 
to the nucleus, or the nuclear receptor can be 
retained in the nucleus in its inactive state. For some 
nuclear receptors, the activating ligand is not 
known, and they are thus called orphan receptors, 
such as the chicken ovalbumin upstream promoter-
transcription factor (COUP) (Li et al. 2009b; Evans 
and Mangelsdorf 2014). There are approximately 
50 nuclear receptors in mammals, whereas in 
Drosophila there are only approximately 20, 
although these represent a member of each receptor 
subfamily (King-Jones and Thummel 2005; 
Thomson et al. 2009).  
 
LXR is an important regulator of glucose, fatty acid 
and cholesterol homeostasis, especially in the liver, 
but also in the adipose tissue (Kalaany et al. 2005; 
Laurencikiene and Ryden 2012; Beaven et al. 2013). 
It functions as a transcriptional activator together 
with its heterodimerization partner RXR (Peet et al. 
1998). The promoter of ChREBP contains a binding 
site for LXR, and it has been shown that LXR can 
regulate the expression of ChREBP in the liver (Cha 
and Repa 2007; Gauthier et al. 2010). However, the 
expression of ChREBP was not altered after high 
sugar feeding in LXR mutant mice, implying that 
the effect of LXR on ChREBP expression is 
independent of nutrition (Denechaud et al. 2008a). 
Next to the LXR/RXR binding site in the ChREBP 
promoter lies another LXR element (LXRE), but 
instead of LXR, it is bound by TR/RXR 
heterodimers. Thyroid hormone receptor (TR) can 
activate ChREBP expression in liver and adipose 
tissue, but activation also seems to be independent 
of nutritional status (Gauthier et al. 2010).   
 
HNF-4α is a conserved nuclear receptor that is 
highly expressed in the liver but also in the gut, 
kidney and pancreas (Duncan et al. 1994; Taraviras 
et al. 1994). It binds DNA as a homodimer and is a 
crucial transcriptional regulator of glucose and lipid 
metabolism in the liver and pancreas (Jiang et al. 
1995; Odom et al. 2004). In addition to directly 
regulating the expression of a number of genes 
involved in glucose and lipid metabolism, HNF-4α 
also regulates the expression of many transcription 
factors involved in metabolic regulation (Kuo et al. 
1992; Taraviras et al. 1994; Bolotin et al. 2010). 
HNF-4α is also known as MODY1 (Maturity-onset 
diabetes of the young 1), since it has been 
discovered as a gene often mutated in this subtype 
of familial type 2 diabetes. Recently, HNF-4α was 
shown to activate ChREBP transcription. More 
importantly, HNF-4α was shown to activate 
ChREBP expression (both ChREBP-α and 
ChREBP-β) in response to glucose in mouse 
primary hepatocytes and HepG2 cells (Meng et al. 
2016), thus providing the long-sought mediator of 
glucose-induced ChREBP expression. Interestingly, 
Meng and colleagues also found that the expression 
of ChREBP-β was not only promoted by the 
previously shown ChREBP-α isoform, but also by 
HNF-4α. HNF-4α is also known to physically 
interact with ChREBP, and this interaction is 
promoted by glucose, suggesting that positive 
feedback loop between ChREBP-α, ChREBP-β 
and HNF-4α (Adamson et al. 2006; Herman et al. 
2012; Meng et al. 2016). The co-operation of HNF-
4α and ChREBP in regulating L-PK expression in 
response to glucose has been also previously 
demonstrated, extending the regulation to their 
target genes as well (Burke et al. 2009). 
1.3. ChREBP/MondoA as a key regulator of 
sugar-induced transcription 
Since their discovery, ChREBP and MondoA have 
proven to be key transcription factors mediating 
glucose induced expression of glycolytic and 
lipogenic genes. The first direct target gene of 
ChREBP to be identified was L-PK (also known as 
liver pyruvate kinase), which catalyzes the final 
step of glycolysis in hepatocytes (Yamashita et al. 
2001). This study also gave the first clue about the 
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glucose-responsiveness of the transcription factors. 
The glucose-dependent activation of MondoA was 
later demonstrated by the use of 2-deoxyglucose (2-
DG), a glucose analog that is phosphorylated but 
not processed further (Stoltzman et al. 2008). In this 
setting, the expression of more than 75% of the 
glucose-responsive genes was shown to be 
dependent on MondoA-Mlx (Stoltzman et al. 2008). 
The tissue specific expression pattern of the 
paralogues is reflected in their downstream target 
genes. However, they also share many targets, 
suggesting a possible functional redundancy 
between ChREBP and MondoA. 
1.3.1. Regulation of glycolysis and lipogenesis by 
MondoA and ChREBP 
The utilization of dietary sugars by different tissues 
depends on their physiological role. Skeletal 
muscle is one the most important sites for dietary 
glucose utilization. Muscles break down glucose 
via the glycolytic pathway to release energy that is 
used for muscle contraction. MondoA expression is 
highest in the skeletal muscle, and most of the 
MondoA-Mlx target genes are involved in the 
glycolytic pathway, such as hexokinase II (HKII), 
lactate dehydrogenase A (LDH-A) and 6-
phosphofructo-2-kinase/fructose-2,6-
bisphosphatase (PFKFB3) (Billin et al. 2000; Sans 
et al. 2006).  
 
Liver is the main site for de novo lipogenesis (DNL), 
where the dietary sugars are converted into TAGs 
and further transported to adipose tissue for storage. 
DNL also takes place in adipose tissue. ChREBP 
displays its highest expression in liver and adipose 
tissue, and the best characterized ChREBP target 
genes include the key lipogenic target genes acetyl-
CoA carboxylase (ACC) and fatty acid synthase 
(FAS) (Ishii et al. 2004; Jeong et al. 2011).  
 
In addition to FAS and ACC, ChREBP-Mlx 
regulates also the expression of a number of other 
genes involved in the lipogenic pathway, including 
the stearoyl-CoA desaturase 1 (SCD-1), fatty acid 
elongase 6 (ELOVL6) and glycerol 3-phosphate 
dehydrogenase (GPDH) (Ishii et al. 2004; Ma et al. 
2005; Ma et al. 2006; Wang et al. 2006; Iizuka et al. 
2009b; Jeong et al. 2011; Poungvarin et al. 2015). 
Moreover, ChREBP-Mlx regulates the glucose-
induced expression of glucose-6-phosphate 
dehydrogenase (G6PDH), the rate limiting enzyme 
of the pentose phosphate pathway (PPP) (Ma et al. 
2006). This step in PPP also produces the NADPH 
required by the DNL pathway. Glycolysis and DNL 
are tightly linked particularly in the liver, where the 
main function for the hepatic glycolytic pathway is 
to transform carbohydrates into fat. ChREBP-Mlx 
is also a key regulator of glycolytic enzymes in the 
liver and adipose tissue (Ishii et al. 2004; Ma et al. 
2005; Ma et al. 2006; Jeong et al. 2011) (Figure 8).  
 
One of the best characterized target genes regulated 
both by MondoA and ChREBP is the thioredoxin-
interacting protein (TXNIP, also known as vitamin 
D3-upregulated protein 1) (Ma et al. 2006; 
Stoltzman et al. 2008; Cha-Molstad et al. 2009). 
TXNIP belongs to the alpha-arrestin protein family 
and is an important regulator of redox signaling. 
Moreover, TXNIP inhibits cellular glucose uptake 
by binding and inducing the endocytosis of GLUT1 
(Wu et al. 2013), thereby providing a potential 
negative feedback loop for glucose metabolism and 
uptake. 
1.3.2. SREBP-1c controls expression of lipogenic 
genes in response to Insulin 
Sterol regulatory element binding proteins 
(SREBPs) are transcription factors that regulate the 
expression of genes involved in lipogenesis and 
cholesterol uptake and synthesis (Briggs et al. 1993; 
Tontonoz et al. 1993; Wang et al. 1993; Magana 
and Osborne 1996; Goldstein et al. 2006). The 
SREBP family consists SREBP-1a, SREBP-1c and 
SREBP-2, which are encoded by two genes, 
SREBPF1 and SREBPF2 (Hua et al. 1995; 
Shimomura et al. 1997).  
 
SREBPs belong to the bHLH/LZ class of 
transcription factors and are synthesized as inactive 
precursor proteins that are anchored to the 
endoplasmic reticulum (ER) membrane (Brown 
and Goldstein 1997; Osborne and Espenshade 
2009). SREBP-2 controls cholesterol metabolism 
genes and its activity is mainly mediated by the 
intracellular cholesterol levels. SREBP-1c is the 
main isoform expressed in the liver and adipose 
tissue, where it is activated by Insulin (Shimomura 
et al. 1997; Kim et al. 1998; Foretz et al. 1999; 
Shimomura et al. 1999; Ferre and Foufelle 2007). 
In contrast to SREBP-2 and SREBP-1a, which are 
induced and activated by low cholesterol levels, 
SREBP-1c levels are regulated by changes in 
nutritional status (Horton et al. 1998; Kim et al. 
1998; Bizeau et al. 2003; Commerford et al. 2004). 
High-carbohydrate diet induces SREBP-1c 
expression, whereas fasting reduces the levels. 
Insulin has been shown to induce both transcription 
and cleavage of SREBP-1c, thus regulating its 
? 28 
activity on multiple levels (Kim et al. 1998; Foretz 
et al. 1999; Hegarty et al. 2005). Glucagon on the 
other hand has been shown to inhibit SREBP-1c 
transcription (Foretz et al. 1999). Furthermore, 
Insulin has been shown to mediate its effect on 
SREBP-1c via the PI3K/AKT/TORC1 pathway 
(Porstmann et al. 2008; Duvel et al. 2010; Li et al. 
2010b). The mechanism by which TORC1 
regulates SREBP-1c activity is still largely 
unresolved. However, inhibitory phosphorylation 
of Lipin-1 by TORC1 in response to Insulin has 
been suggested to increase SREBP-1 
transcriptional activity (Peterson et al. 2011). 
 
The transcriptional regulation of SREBP-1c is 
known to require the Insulin-TORC1 axis, which 
ultimately leads to a feed-forward stimulation 
where SREBP-1c can autoregulate its own 
expression via SREs present in their promoters 
(Sato et al. 1996; Amemiya-Kudo et al. 2000; Li et 
al. 2010b). LXRα has been also shown to induce the 
transcription of SREBP-1c in response to dietary 
cholesterol (Repa et al. 2000). In addition to direct 
transcriptional regulation, LXR is required for the 
Insulin-mediated activation of SREBP-1c, further 
linking cholesterol and fatty acid metabolism (Chen 
et al. 2004). SREBP-1c promoter also contains a 
ChoRE element, and ChREBP has been shown to 
mediate the glucose-induced expression of SREBP-
1c (Jeong et al. 2011; Poungvarin et al. 2015). 
 
SREBP-1c is a key regulator of DNL in the liver, 
and its target genes include acetyl-CoA synthetase 
(ACS), ACC, FAS, SCD-1 and glycerol-3-
phosphate acyl-transferase (GPAT) (Edwards et al. 
2000). The regulation of glucokinase (GK) 
expression is also dependent on Insulin and SREBP 
(Van Schaftingen 1994; Foretz et al. 1999; Kim et 
al. 2004). However, the Glucokinase regulatory 
protein (GKRP) that controls GK activity, is 
regulated by glucose and ChREBP (Ma et al. 2006; 
Jeong et al. 2011), thus providing a synergistic 
regulatory mode for glucokinase, an important 
sensor and regulator of whole body glucose-levels 
and glucose metabolism.  
Figure 8. Regulation of hepatic glycolysis and de novo lipogenesis by ChREBP-Mlx 
Enzymes regulated by ChREBP-Mlx are highlighted in red.  
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1.3.3. Coordinated regulation of de novo 
lipogenesis by ChREBP and SREBP 
For a long time, SREBP-1c was thought to be the 
master regulator of DNL. However, expression of 
lipogenic genes is reduced only by approximately 
50% in the livers of SREBP-1c knockout mice (KO) 
(Liang et al. 2002). Moreover, although SREBP1-
1c is expressed in adipose tissue, the expression of 
lipogenic enzymes in the adipose tissue of SREBP 
KO mice is normal, and thus it has been suggested 
that DNL in adipose tissue is regulated solely by 
ChREBP (Shimano et al. 1997; Shimomura et al. 
1997; Herman et al. 2012). 
 
Although the role of SREBP-1c as a key regulator 
of DNL is indisputable, the characterization of 
ChREBP has provided a more complete picture of 
transcriptional regulation of DNL. Today it is 
known that SREBP-1c is regulating DNL together 
with other transcription factors such as ChREBP, 
HNF-4α and LXR, in a highly concerted manner 
(Chen et al. 2004; Dentin et al. 2005b; Wong and 
Sul 2010). Most of the lipogenic genes harbor both 
SRE and ChoRE elements in their promoters, 
highlighting the importance of co-regulation of 
DNL both by Insulin and glucose initiated signals 
(Shih et al. 1995; Rufo et al. 2001; Griffin et al. 
2007; Wong and Sul 2010) (Figure 9). In addition, 
the Patatin-like phospholipase domain-containing 3 
(PNPLA3), better known as Adiponutrin, promotes 
hepatic lipid synthesis and is regulated both by 
ChREBP and SREBP in response to glucose and 
Insulin, respectively (Dubuquoy et al. 2011; 
Kumari et al. 2012; Perttila et al. 2012). 
1.3.4. ChREBP-Mlx controls the glucose 
induced expression of genes related to circadian 
rhythm  
MondoA and ChREBP have shown to act mainly as 
transcriptional activators, however their role in 
glucose induced transcriptional repression has been 
also suggested by a number of studies (Ma et al. 
2006; Noordeen et al. 2010; Arden et al. 2011; 
Boergesen et al. 2011; Jeong et al. 2011; Noriega et 
al. 2011; Poungvarin et al. 2015). Interestingly, 
MondoA/ChREBP-Mlx target genes also include 
many transcriptional regulators, suggesting that 
MondoA/ChREBP-Mlx mediates some of its 
effects via a secondary tier of transcription factors, 
including transcriptional repressors. 
 
ChREBP regulates the expression krüppel-like 
factor 10 (KLF10) and DEC1 (BHLHB2/ 
BHLHE40/STRA13/STRA14) in response to 
glucose (Iizuka and Horikawa 2008; Iizuka et al. 
2011). KLF10, also known as TGFβ inducible early 
gene-1 (TIEG), is an ubiquitously expressed protein 
originally identified as a cell cycle regulator and 
potential tumor suppressor (Subramaniam et al. 
2010; Song et al. 2012). KLF10 expression levels 
are regulated by the circadian clock, a molecular 
timing system composed of multiple transcriptional 
regulators that coordinate physiology, metabolism 
and behavior in response to external light-dark 
cycle input (Guillaumond et al. 2010; Gooley 2016; 
McGinnis and Young 2016). The core clock is 
composed of the four clock proteins Clock, Bmal1, 
Per and Cry. Clock/Bmal1 heterodimers activate 
the expression of PER and CRY, which in turn 
heterodimerize and inhibit the function of 
Clock/Bmal1 via direct interaction (Partch et al. 
2014). Furthermore, KLF10 has been shown to be 
an important regulator of lipid and carbohydrate 
metabolism (Guillaumond et al. 2010). DEC1 
(Deleted in Esophageal cancer 1) and its paralogue 
Figure 9. Coordinated regulation of DNL by ChREBP 
and SREBP 
ChREBP and SREBP regulate the expression of glycolytic 
and lipogenic genes in response to glucose and Insulin, 
respectively. Modified from Postic & Girard, 2008. 
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DEC2 regulate the clock by inhibiting the 
expression of PER1 via competing with 
Clock/Bmal1 for binding to an E-box in the PER1 
promoter (Honma et al. 2002). Clock/Bmal1 in turn 
directly regulates expression of DEC1 and DEC2, 
thus forming a negative feedback loop in the clock 
(Kato et al. 2014).  
 
Interestingly, it was shown already in 1986 by 
Newman & Hospod that the uptake of glucose in 
the suprachiasmatic nucleus (SCN) of the brain 
differs between day and night (Newman and 
Hospod 1986; Hamada et al. 1993), suggesting that 
circadian rhythm controls metabolism and feeding 
behavior. SCN is the area of the hypothalamus that 
contains the master clock, however the peripheral 
tissues also express and have functional, self-
sustained molecular clocks (Yoo et al. 2004). 
Today, the dysfunction of circadian rhythm has 
been linked to many metabolic diseases, for 
example metabolic syndrome, obesity and diabetes 
(Spiegel et al. 2005; Turek et al. 2005; Knutson et 
al. 2007; Arble et al. 2009; Marcheva et al. 2010; 
Maury et al. 2010; Shimba et al. 2011). For example, 
loss of Bmal1 specifically in the pancreas leads to 
impaired Insulin production and severe glucose 
intolerance (Sadacca et al. 2011), whereas loss of 
Bmal1 in the adipose tissue causes a shift in the 
diurnal food intake rhythm, which leads to obesity 
in mice (Paschos et al. 2012).  
 
The circadian rhythm regulated glucose uptake and 
the finding that ChREBP-Mlx regulates some of the 
key regulators and mediators of the clock suggest 
that nutrient sensing, metabolism and circadian 
rhythm are tightly connected processes. The details 
are only beginning to emerge, along with the role of 
MondoA and ChREBP in these processes.  
1.3.5. ChREBP and MondoA in human disease 
ChREBP and MondoA, together with their binding 
partner Mlx, are key transcriptional regulators of 
carbohydrate and lipid metabolism. Studies on 
ChREBP and MondoA mutant mice have 
confirmed their critical role in metabolic regulation. 
ChREBP-/- mice display various metabolic defects, 
including reduced liver fatty acid levels and 
adiposity, hyperglycemia, and increased Insulin 
and glycogen levels (Iizuka et al. 2004). ChREBP 
knockout mice are also highly sugar intolerant and 
are unable to survive on a high-carbohydrate diet. 
However, the underlying reason for the sugar 
intolerance has not been explored (Iizuka et al. 
2004). MondoA knockout mice are viable, have a 
normal body weight, fasting glucose and plasma 
lipid profiles (Imamura et al. 2014). However, due 
to defective glycolysis, the animals use fatty acid 
oxidation to provide energy, and the pyruvate is 
shunted to lactate which is reflected by the high 
plasma lactate levels of MondoA-/- mice (Imamura 
et al. 2014). Perhaps not surprisingly, dysregulation 
of both ChREBP and MondoA has been linked to 
many human diseases, including type 2 diabetes, 
metabolic syndrome and cancer.  
 
ChREBP was originally identified as a gene deleted 
in William-Beuren syndrome, a 
neurodevelopmental disorder characterized by 
multiple physiological abnormalities, including 
cardiovascular complications and diabetes, which 
is observed in 75% of adult patients (de Luis et al. 
2000; Cairo et al. 2001; Pober 2010). Variants of 
the human ChREBP (also known as MLXIPL) have 
been associated with high plasma triglyceride levels 
as well as with elevated concentrations of plasma 
liver enzymes and increased risk of coronary artery 
disease (Kathiresan et al. 2008; Kooner et al. 2008; 
Wang et al. 2008; Willer et al. 2008; Pan et al. 
2009). Most recently, the expression levels of the 
novel ChREBP-β isoform in adipose tissue have 
been found to correlate positively with the insulin 
sensitivity in humans (Herman et al. 2012; Kursawe 
et al. 2013). On the other hand, increased ChREBP-
β activity has been linked to elevated DNL in 
obesity (Eissing et al. 2013). 
 
Hepatic ChREBP activity has been suggested to 
play a role in the pathobiology of nonalcoholic fatty 
liver disease (NAFLD), the most common cause of 
liver dysfunction in Western countries (Denechaud 
et al. 2008b). NAFLD is a presenting symptom of 
metabolic syndrome. It is characterized by steatosis 
and abnormal fat accumulation in the hepatocytes, 
and it is tightly linked to type 2 diabetes and obesity 
(Marchesini et al. 2001; Charlton 2004; Cheung and 
Sanyal 2010). NAFLD can develop into non-
alcoholic steatohepatitis (NASH), which in turn can 
lead to cirrhosis and liver cancer (Hassan et al. 
2014). Although overexpression of ChREBP in 
mice leads to induction of lipogenesis and hepatic 
steatosis, increased ChREBP activity also has 
beneficial effects, for example improved glucose 
tolerance (Benhamed et al. 2012). In fact, ChREBP 
expression has been found to correlate positively 
with the degree of hepatic steatosis and negatively 
with insulin resistance in NASH patients, 
suggesting that the two metabolic conditions can 
occur independently, and that modulation of 
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ChREBP activity can be used to protect NAFLD 
patients from developing diabetes (Benhamed et al. 
2012).  
 
Modulation of ChREBP activity has been also 
studied in the commonly used ob/ob obesity mouse 
model (Ingalls et al. 1950; Dentin et al. 2006; Iizuka 
et al. 2006). The ob/ob mice also develop insulin 
resistance and are used as a model for type 2 
diabetes (Genuth 1969; Beloff-Chain et al. 1975). 
Identification of the mutation leading to the various 
metabolic defects of ob/ob mice led to the discovery 
of Leptin hormone, a satiety signal the deficiency 
of leads to excessive feeding and obesity in ob/ob 
mice (Friedman et al. 1991; Zhang et al. 1994; 
Campfield et al. 1995). Interestingly, ob/ob mice 
with liver-specific inhibition of ChREBP, or ob/ob 
–ChREBP-/- double mutant mice, display markedly 
improved metabolic profiles, including reduced 
lipogenic gene expression, hepatic DNL and 
enhanced glucose tolerance and insulin sensitivity 
(Dentin et al. 2006; Iizuka et al. 2006).  
 
Finally, both MondoA and ChREBP have been 
suggested to play a role in the metabolic 
reprogramming of cancer cells. Tumor cells often 
rely on glycolysis to provide the high amount of 
energy and carbons needed for anabolic reactions 
such as nucleotide biosynthesis that drive the fast 
growth and proliferation. This phenomenon is also 
known as the Warburg effect. Increased ChREBP 
activity in colorectal and hepatic cancer cell models 
has been shown to promote anabolic pathways 
including glycolysis, DNL and nucleotide 
biosynthesis (Tong et al. 2009). Loss of MondoA in 
tumors that rely on deregulated Myc in growth 
leads to synthetic lethality, suggesting that 
MondoA is required by the Myc-dependent 
metabolic reprogramming of cancer cells (Carroll 
et al. 2015). 
1.4. Drosophila melanogaster as a model 
organism 
The basis for modern genetics was established in 
the early 1900s in the lab of Thomas Hunt Morgan 
who was using the fruit fly, Drosophila 
melanogaster, in his studies. He was able to show 
that chromosomes, and later genes within them, 
formed the basis of heredity (Morgan 1910; 
Morgan et al. 1920). These findings gave Morgan 
the Nobel Prize in Physiology in 1933. Morgan’s 
work also made Drosophila very popular among 
scientists around the world, becoming one of the 
most favored model organisms, which it still is 
today. Altogether, the work done with Drosophila 
has resulted in 7 Nobel prizes in Physiology and 
Medicine, among them Morgan’s former student 
Herman Muller, who discovered that X-ray 
irradiation causes mutations (Muller 1927). Other 
famous discoveries include the conserved homeotic 
HOX-genes that control embryonic development 
and patterning, and most recently work that 
elucidated some fundamental aspects of innate 
immunity (Lewis 1978; Nusslein-Volhard and 
Wieschaus 1980; Lemaitre et al. 1996). 
 
Drosophila’s popularity as a model organism can 
be attributed to many factors, including its low cost, 
small size, short generation time and ease of 
maintenance (Figure 10). Its small genome (only 4 
pairs of chromosomes) was fully sequenced in 2000 
and although it is only about 5% of the size of the 
human genome (0.18 Gb vs. 3.3Gb), the difference 
in the number of genes is surprisingly small (Adams 
et al. 2000). Drosophila genome encodes 
approximately 15 000 genes, whereas in humans 
the number has been estimated at 20 000 (Adams et 
al. 2000; Kornberg and Krasnow 2000; Lander et al. 
2001; Ezkurdia et al. 2014). This difference arises 
mainly from the presence of several paralogous 
genes in mammals, whereas there is less 
redundancy in Drosophila - often an advantage in 
genetic studies. Male flies also lack meiotic 
recombination, further simplifying the genetics in 
fly experiments.  
 
It has been estimated that more than 75% of all 
human disease genes have functional orthologues in 
flies (Reiter et al. 2001). Moreover, the extensive 
genetic toolkit available, including in vivo RNAi 
and UAS-ORF libraries, tissue specific GAL4-
driver lines, and the recessive lethal balancer 
chromosomes that carry visible genetic markers and 
do not undergo crossing over, allowing lethal 
alleles to be maintained as stable heterozygous 
stocks, have greatly contributed to Drosophila’s 
success as a model organism. The GAL4/UAS 
(galactose gene transcription factor 4/upstream 
activation sequence) system allows 
spatiotemporally controlled transgene expression in 
vivo (Brand and Perrimon 1993), and the fly 
research community has made the majority of stock 
lines available in public stock centers such as 
Vienna Drosophila RNAi Center (VDRC) and 
Bloomington Drosophila Stock Center (BDSC). 
Recent developments in targeted genome editing 
technologies, especially the CRISPR/Cas9 system,  
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has also enabled rapid generation of mutant and 
transgenic flies (Bassett et al. 2013).   
 
Drosophila has a long history as a model organism 
to study development and neurobiology. However, 
the use of fly as a model to study mammalian 
physiology and metabolism has only started to 
reach its full potential. Flies were long thought to 
differ from mammals to the extent that they do not 
share the same principles of physiology, a view that 
has proved to be largely incorrect. Although fruit 
flies differ greatly from vertebrates in their 
morphology, they have basically the same organ 
systems, performing the same functions as their 
mammalian counterparts (Figure 11). In addition, 
the rapid development of a vast array of basic and 
more sophisticated metabolic assays, has made 
Drosophila a popular model for human metabolic 
diseases such as obesity and type 2 diabetes (Baker 
and Thummel 2007; Leopold and Perrimon 2007; 
Rajan and Perrimon 2013; Owusu-Ansah and 
Perrimon 2014; Padmanabha and Baker 2014; 
Tennessen et al. 2014). 
1.4.1. Physiology and tissue organization of 
Drosophila melanogaster 
Drosophila maintains its metabolic homeostasis 
with the action of the same analogous metabolic 
organs and signaling pathways as mammals. 
Although there are clear physiological and 
anatomical differences between the fly and 
mammals, functional analogy can be found from 
many aspects in their physiology. The fly 
undergoes major morphological and physiological 
rearrangements during its development from an 
embryo into an adult, via 3 larval stages (instars) 
interrupted by molts, and a pupal stage that is 
finalized by a complete metamorphosis (Figure 10). 
Metamorphosis and the timing of larval molting are 
controlled by steroid hormones, which are secreted 
in response to growth signals by the ring gland 
located in the brain (Gilbert et al. 2002; Yamanaka 
et al. 2013). The metabolism of larval stages is 
markedly different from the adult in that the larvae 
are feeding continuously and accumulate a 
substantial amount of fat and glycogen to carry 
through the pupal stage. Adult flies do not grow, 
and their size is determined by the nutritional status 
and growth rate during the larval stages (Edgar 
2006; Mirth and Shingleton 2012). The change in 
regulation and downstream effects of many 
signaling pathways have been shown to reflect this 
transition from the active growth period of larvae 
into maintenance of metabolic homeostasis in the 
adult.  
 
Drosophila, like most other invertebrates, have an 
“open” circulation system where the blood-like 
Figure 10. Drosophila lifecycle 
The development of an adult fly from an egg takes optimally ~10 days. Flies undergo a complete metamorphosis from 
an embryo to adult via three larval stages and a pupal stage.  
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fluid called hemolymph circulates 
throughout the body aided by the 
pumping action of a tubular heart 
(Choma et al. 2011). Although 
Drosophila has an open 
circulation, its tubular, beating 
heart has many characteristics 
similar to vertebrate heart (Bier and 
Bodmer 2004). Another special 
characteristic is the use of 
trehalose, a disaccharide formed of 
two glucose molecules, as a form of 
circulating storage sugar (Reyes-
DelaTorre 2012). Trehalose is 
considered to be an adaptation for 
flight, which requires high levels of 
circulating sugars. One of the 
major differences between 
mammals and fly is the regulation 
of glucose transport in response to 
Insulin. In mammals, GLUT4 transporter 
translocates to the plasma membrane in response to 
Insulin, however in the fly, Insulin does not seem to 
control the rate of glucose uptake (Ceddia et al. 
2003). Another key difference is that flies are not 
able to synthesize cholesterol (Clark and Block 
1959; Clayton 1964).  
 
Most Drosophila organs are morphologically 
different from their mammalian counterparts but 
still carry out the same functions. The fly gut, 
although structurally much more simple, is a highly 
compartmentalized organ divided into foregut, 
midgut and hindgut, which display functional 
similarities to the human gastrointestinal tract 
(Buchon et al. 2013a). The foregut is in charge of 
food mixing, detoxification and storage, and the 
midgut is the main site for digestion and food 
absorption. Water reabsorption and waste excretion 
takes place in the hindgut. Furthermore, the midgut 
has been shown to be regionally organized into 14 
subregions displaying distinct gene expression 
patterns and morphology, and also into functionally 
diverse intestinal cell types similar to the cells in the 
mammalian intestinal epithelium (Buchon et al. 
2013b; Dutta et al. 2015). Malpighian tubules, or 
renal tubules, are the major excretory and 
osmoregulatory organs of the fly and thus 
functionally analogous to vertebrate kidneys (Jung 
et al. 2005).  
 
The fat body is a specialized organ, functionally 
orthologous to mammalian adipose tissue and liver, 
composed of adipocytes that are organized into 
loose sheet-like structures. The fat body is 
distributed throughout the body and it serves both 
as a nutrient sensor as well as a site for triglyceride 
and glycogen storage (Colombani et al. 2003). It is 
the major metabolic organ, synthetizing and 
secreting the majority of circulating proteins and 
metabolites that in turn control growth and 
metabolism in other sites of the body (Arrese and 
Soulages 2010). In fact, the fat body is not only in 
charge of storing nutrients, but acts as an endocrine 
organ that regulates organismal growth and 
development by integrating nutritional and 
hormonal signals (Colombani et al. 2003; Arrese 
and Soulages 2010).  
 
The Insulin producing β-cells of pancreas have 
functional counterparts in the fly brain, where 
Insulin-producing cells (IPCs) secrete Drosophila 
Insulin-like peptides (dILPs) into the circulation 
(Brogiolo et al. 2001; Rulifson et al. 2002; 
Broughton et al. 2005). dILPs are also secreted 
from other organs and display developmental stage-
dependent expression patterns. For example, from 
the eight dILPS encoded by the Drosophila genome, 
only dILP2, 3 and 5 are secreted from IPCs, dILP4 
is secreted by the embryonic and larval gut and 
dILP6 by the fat body (Gronke et al. 2010; 
Padmanabha and Baker 2014).  
 
The ring gland is located next to the IPCs and is a 
key neuroendocrine organ composed of the corpora 
cardiaca (CC), corpora allata (CA) and prothoracic 
gland (PG). CC is analogous to mammalian 
pancreatic α-cells and secretes the Glucagon-like 
Figure 11. The functional conservation of Drosophila organ systems 
Comparison of the mammalian and Drosophila organ systems. Modified 
from Diop & Bodmer 2015. 
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peptide adipokinetic hormone (AKH) (Kim and 
Rulifson 2004). AKH, like its mammalian 
counterpart Glucagon, regulates circulating sugar 
levels. It binds to its receptors in the fat body and 
activates Glycogen phosphorylase, which induces 
the breakdown of glycogen and secretion of 
trehalose into the circulation (Staubli et al. 2002; 
Van der Horst 2003; Kim and Rulifson 2004; Lee 
and Park 2004). Juvenile hormone secreted by CA, 
and Ecdysone and Prothoracicotropic hormone 
(PTTH) secreted by PG, control the molting and 
metamorphosis in insects (Doane 1973; McBrayer 
et al. 2007).  
1.4.2. Nutrient sensing pathways in Drosophila 
The metabolic homeostasis of flies and mammals is 
controlled by the same basic endocrine hormones. 
For example, the counteracting hormones AKH and 
dILPs regulate circulating glucose levels similarly 
to Glucagon and Insulin. The brain dILPs are 
secreted into the circulation in response to feeding, 
promoting the uptake of sugars from the 
hemolymph and their storage as glycogen and 
TAGs, whereas AKH stimulates the breakdown of 
glycogen and TAGs during starvation (Kim and 
Rulifson 2004; Lee and Park 2004; Geminard et al. 
2009). Loss of dILPs leads to hyperglycemia, 
similar to mammals (Rulifson et al. 2002).  
 
The major signaling pathways involved in lipid 
biosynthesis, storage and mobilization are highly 
conserved in Drosophila. Like other metabolic 
pathways, lipid metabolism is more simple in flies 
when compared to mammals that often have 
multiple paralogues for many key metabolic 
regulators and enzymes. A special characteristic of 
Drosophila lipid metabolism is the inability to 
synthesize cholesterol, which flies require from 
their diet (Clark and Block 1959; Clayton 1964). In 
line with this, Drosophila SREBP activity is not 
regulated by sterols but by 
phosphatidylethanolamine, and SREBP is thought 
to regulate only the synthesis of fatty acids 
(Dobrosotskaya et al. 2002; Seegmiller et al. 2002). 
Drosophila SREBP mutants die as 2nd instar larvae 
and display markedly reduced fatty acid synthesis. 
The role of Drosophila SREBP as a key regulator 
of fatty acid synthesis is supported by the finding 
that the lethality of SREBP mutants can be rescued 
by supplementing fatty acids, namely oleate, in 
their diet (Kunte et al. 2006).   
 
The fat body serves as the main site of fat storage 
in the fly. Flies have also a specialized group of 
cells, termed oenocytes, which have the ability to 
mobilize stored lipids from the fat body, similarly 
to the mammalian liver (Gutierrez et al. 2007). 
During nutrient deprivation, AKH stimulates the 
breakdown of glycogen and lipolysis (Kim and 
Rulifson 2004; Lee and Park 2004). The regulation 
and the key enzymes of lipolysis are conserved in 
the fly. The adipocytes in the fat body store lipids 
in droplets, which are coated by lipase-protecting 
proteins, including perilipins (Teixeira et al. 2003; 
Gronke et al. 2005). The Drosophila genome 
encodes two perilipins that are thought to display 
opposing functions, with Lsd-2 (Lipid storage 
droplet-2) protecting lipid droplets from lipolysis, 
and Lsd-1 promoting lipid mobilization (Teixeira et 
al. 2003; Gronke et al. 2005; Beller et al. 2010; Bi 
et al. 2012). The expression of brummer, the 
Drosophila homologue of the apidocyte 
triglyceride lipase (ATGL), is upregulated during 
starvation and is essential for mobilization of lipids 
(Gronke et al. 2005). 
 
Metabolic signaling pathways are also highly 
conserved in the fly, and the groundwork for 
resolving many key aspects of nutrient sensing and 
signaling in mammals has been done in fly studies. 
One the best and most studied nutrient sensing and 
signaling systems is the Insulin/Insulin-like growth 
factor (IGF) and TOR signaling pathway, which 
controls growth and metabolism both in humans 
and the fly. In fact, Drosophila has become one the 
most important model systems to study Insulin 
signaling (Teleman 2010). The core pathway and its 
functions are highly conserved but compared to 
mammals, the fly displays a reduced pathway with 
less complexity. For example, the fly genome 
encodes only single homologues for the insulin 
receptor (InR), insulin receptor substrate (chico) 
and FOXO (foxo) (Fernandez et al. 1995; Bohni et 
al. 1999; Puig et al. 2003; Teleman 2010). The 
single InR is activated by all dILPs, however 
different dILPs seem to respond to different 
nutritional cues (Ikeya et al. 2002). dILP2 secretion 
is promoted by amino acids, whereas the release of 
dILP3 from IPCs is dependent on sugars (Geminard 
et al. 2009; Kim and Neufeld 2015). The fat body 
specific dILP6 is expressed in response to 
starvation and regulates the expression and release 
of dILP2 from the IPCs (Okamoto et al. 2009; 
Slaidina et al. 2009; Bai et al. 2012). 
 
The role of fat body as an important nutrient sensor 
regulating whole-body metabolism has been shown 
by several studies, which have also given clues 
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about nutrient-dependent regulation of conserved 
signaling pathways. For example, the amino acid 
transporter Slimfast mediates the effects of whole-
body amino acid levels to TOR signaling in the fat 
body (Colombani et al. 2003). Fat body specific 
knockdown of slimfast phenocopies the growth 
suppressive phenotype of TOR signaling inhibition 
or amino acid starvation. The fat body also secretes 
many peptides, cytokines and other endocrine 
molecules, which signal other sites of the body 
about the nutritional status. Unpaired 2 (Upd2), the 
functional homologue of mammalian Leptin, is 
secreted by the fat body in response to feeding 
(Rajan and Perrimon 2012). Similar to the 
mammalian Leptin, Upd2 stimulates the 
JAK/STAT pathway, which ultimately leads to the 
secretion of dILPs (Rajan and Perrimon 2012). 
Whereas Slimfast responds to amino acids, Upd2 
secretion is promoted only by fats and sugars 
(Colombani et al. 2003; Rajan and Perrimon 2012). 
Recently, an amino acid sensitive adipokine and 
TNF-α homologue Eiger was shown to be secreted 
from the fat body in response to amino acid 
starvation, and to mediate the reduced expression of 
dILPs by binding to its receptor Grindelwald in the 
IPCs (Agrawal et al. 2016). The epidermal growth-
like factors Growth-blocking peptide 1 and 2 (Gbp1 
and Gbp2) in turn are produced and secreted from 
the fat body in response to increased amino acid 
levels and TOR signaling (Koyama and Mirth 
2016). Gbp1 and Gbp2 act directly in the brain and 
stimulate dILP secretion (Koyama and Mirth 2016). 
 
In addition to Leptin, multiple other hormonal 
factors have been shown to be activated and 
secreted in response to carbohydrates in Drosophila. 
CCHamide-2 (CCHa2) is expressed and secreted by 
the gut and fat body in response to sugars. It signals 
directly to the IPCs and triggers the expression and 
release of dILP5 and also the release of dILP2 by 
binding to its receptor CCHa2-R (Sano et al. 2015). 
The TGF-β/Activin-like ligand Dawdle is also 
secreted from the fat body in response to sugars, 
regulating the release of dILP2 and dILP5 from the 
IPCs (Ghosh and O'Connor 2014). Moreover, 
Dawdle-activated Activin signaling in the gut has 
been shown to mediate the sugar-induced 
repression of amylases (Hickey and Benkel 1982; 
Benkel and Hickey 1987; Chng et al. 2014). High-
sugar feeding also triggers the production and 
release of Neural Lazarillo (NLaz), a lipocalin 
peptide highly homologous to mammalian Retinol 
binding protein 4 (RBP4) and Apolipoprotein D 
(ApoD) (Pasco and Leopold 2012). High serum 
levels of RBP4 and ApoD have been associated 
with development of insulin resistance (Yang et al. 
2005; Graham et al. 2006; Do Carmo et al. 2009), 
which is also true in Drosophila, where partial 
NLaz deficiency protects against high-sugar diet 
induced insulin resistance (Pasco and Leopold 
2012). 
 
The Drosophila genome encodes a minimal Myc-
Max-Mnt-Mlx-Mondo(ChREBP) network 
composed of a single copy of each gene (Figure 5). 
At the time when this thesis was started, there were 
no published studies on Drosophila Mondo-Mlx. 
However, the conserved glucose-sensing function 
of Mondo had been suggested by a mammalian in 
vitro study, where the replacement of the mouse 
ChREBP N-terminal region including the glucose 
sensing module (GSM) with the corresponding 
Drosophila Mondo region retained the glucose-
inducible activation of the reporter (Li et al. 2006). 
In addition, the expression of mlx has been shown 
to be upregulated in response to high sugar diet in 
Drosophila larvae (Zinke et al. 2002), suggesting a 
conserved role in sugar sensing. An observation 
described in a review article from the lab of Donald 
Ayer also suggests that Drosophila Mondo is 
necessary for viability, since partial loss of mondo 
led to reduced viability (Billin and Ayer 2006). 
They also proposed a synthetic lethal genetic 
interaction between Drosophila Myc and Mondo: 
whereas the myc null mutants were viable, loss of 
both myc and mondo led to a complete lethality with 
no adult survivors.   
1.4.3. Studies on nutrient-regulated 
transcription in Drosophila  
Flies develop obesity and insulin resistance in 
response to high carbohydrate and high fat diets in 
a manner similar to mammalian models (Surwit et 
al. 1988; Musselman et al. 2011; Pasco and Leopold 
2012). Additionally, the analysis and phenotyping 
of several different mutant flies have indicated that 
the pathobiology of several metabolic diseases is 
conserved in the fly (Baker and Thummel 2007; 
Teleman 2010). This makes Drosophila an 
appealing model organism to study the molecular 
mechanism underlying various human complex 
diseases. A major advantage compared to human 
studies is the possibility to manipulate and strictly 
control the environmental conditions, especially the 
diet. Moreover, unlike for example mice, 
Drosophila larvae eat continuously, which allows a 
reliable assessment of metabolic effects in response 
to dynamic dietary treatments.  
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Metabolic enzymes and regulators are often 
regulated at the transcriptional level. Thus much of 
research has focused on identifying genes that are 
differentially expressed in response to different 
dietary interventions. The major groundwork for 
identifying genes that are regulated 
transcriptionally in response to nutritional signals 
came from the study by Zinke and collegues in 
2002. In this study, they investigated the gene 
expression (Affymetrix microarray) profiles of 
larvae after 1, 4 and 12 hours on high-sugar diet 
feeding or starvation, and as expected, found that 
the number of genes that were differentially 
expressed increased as a function of time (Zinke et 
al. 2002). The gene that displayed the highest and 
earliest expression response to sugar feeding was 
found to be a zinc finger transcription factor 
CG3850, which they named sugarbabe (sug). The 
sugar-induced expression of sugarbabe was found 
to be most prominent in the fat body, gut and 
Malpighian tubules, and the study suggested that it 
has a role in transcriptional repression of 
downstream target genes in response to dietary 
sugars (Zinke et al. 2002).  In addition to sugarbabe, 
among the genes that responded most strongly to 
dietary sugars were acetyl-CoA carboxylase (ACC, 
CG11198), acetyl-CoA synthase (AcCoAS, 
CG9390), ATP citrate lyase (ATPCL, CG8322), 
glucose-6-phosphate dehydrogenase 
Zwischenferment (Zw, CG12529) and the 
phosphoserine phosphatase astray (aay, CG3705).  
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2. AIMS OF THE STUDY 
 
Metabolic diseases, such as type 2 diabetes, are the leading cause of death in developed countries (WHO 
2016). Excess intake of calories, especially in the form of added sugars, has been suggested to underlie this 
epidemic (Lustig et al. 2012). However, individuals display remarkable differences in their physiological 
and metabolic responses to nutrients. Also considerable natural variation in diet exists between animal 
species. Although the systemic control of glucose homeostasis by Insulin and Glucagon is well-understood, 
the regulation and control of sugar-induced metabolic processes at the cellular level are still largely 
unresolved. ChREBP/MondoA-Mlx transcription factors are activated by sugars, and their target genes 
include mainly glycolytic and lipogenic genes. Interestingly, mice lacking ChREBP are intolerant to dietary 
carbohydrates (Iizuka et al. 2004), suggesting a role for ChREBP-Mlx in regulating organismal sugar 
tolerance. Variants of human ChREBP have also been associated with increased triglyceride levels, a 
predisposing factor for the development of type 2 diabetes (Kathiresan et al. 2008; Kooner et al. 2008; 
Wang et al. 2008; Willer et al. 2008; Pan et al. 2009). The role of mammalian ChREBP/MondoA-Mlx in 
sugar-induced transcription has been studied mainly in an in vitro setting. Mondo and Mlx proteins are well 
conserved throughout metazoan evolution. The Drosophila genome encodes single orthologues of 
ChREBP/MondoA and Mlx, which we call Mondo and Mlx, respectively.  
 
 
The specific aims of this thesis were: 
 
 
I   Characterization of the in vivo role of the Drosophila Mondo-Mlx 
 
II   To study the role of Mondo-Mlx in sugar-induced transcription and to identify the targets of 
Mondo-Mlx 
 
III  To further characterize the role of the secondary tier of transcriptional effectors downstream of 
Mondo-Mlx in sugar metabolism 
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3. MATERIALS AND METHODS 
 
Fly strains 
 
Strain      Source 
P[XP]bigmaxd07258    BDSC 
mlx1      Havula et al. 2013 
UAS-Mlx FLAG     Havula et al. 2013 
UAS-Aldh-III     Havula et al. 2013 
UAS-Mlx RNAi 110630 KK   VDRC 
UAS-Mondo RNAi 109821 KK   VDRC 
UAS-Cabut RNAi 4427R-1   NIG 
UAS-Aldh-III RNAi 107110 KK  VDRC 
UAS-FAS RNAi 108339 KK   VDRC 
UAS-PFK2 RNAi 25959 GD   VDRC 
UAS-CG7882 RNAi 109918 KK  VDRC 
UAS-Zw RNAi 101507 KK   VDRC 
UAS-Gs2 RNAi 32929 GD   VDRC 
UAS-aay RNAi 110661 KK   VDRC 
UAS-daw RNAi 105309 KK   VDRC 
UAS-Smox RNAi 105687 KK   VDRC 
Sug17Δ      Mattila et al. 2015 
UAS-sug      Zinke et al. 2002 
UAS-sug RNAi1 3850R-1   NIG 
UAS-sug RNAi2 3850R-3   NIG 
Df(2R)Exel7123     BDSC 
tub-GAL4     BDSC 
ppl-GAL4     BDSC 
r4-GAL4      BDSC 
Elav-GAL4     BDSC 
Mef2-GAL4     BDSC 
Ubi-GAL4     BDSC 
Hs-GAL4      BDSC  
Cg-GAL4      BDSC 
Fb-GAL4      BDSC 
NP1-GAL4     BDSC 
 
Stock centers: 
BDSC (Bloomington Drosophila Stock Center) 
NIG (Fly Stocks of National Institute of Genetics, Japan) 
VDRC (Vienna Drosophila Resource Center) 
 
 
 
Fly husbandry 
 
Fly stocks were maintained at +25°C on standard food containing 0.6% (w/v) agar, 3.2% (w/v) semolina, 
6.5% (w/v) malt, 1.8% (w/v) dry baker’s yeast, 2.4% (v/v) nipagin and 0.7% (v/v) propionic acid.  
 
The defined nutrient studies were conducted in food containing 0.5% (w/v) agar, 2.4% (v/v) nipagin and 
0.7% (v/v) propionic acid in PBS supplemented with varying concentrations of dry baker’s yeast (w/v), 
sucrose (w/v), glucose (w/v), fructose (w/v) or potato starch (w/v). Larvae were grown at controlled density 
(30 larvae per vial). 
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Method Reference Used in publication 
Generation of transgenic fly strains I, II I, II 
Generation of mutant fly by imprecise P-
element excision  
Venken and Bellen 
2005 Nature I 
Generation of mutant fly by CRISPR/CAS9 Kondo and Ueda 2013 II 
in vivo UAS-GAL4 methods I, II I, II
Recombinant protein expression and purification I I 
SDS-PAGE I I 
Western blotting I I 
Co-immunoprecipitation (Co-IP) I I 
Standard RNA and DNA techniques I, II I, II 
RNA extraction I, II I, II 
Quantitative real-time PCR (qRT-PCR) I, II I, II 
Chromatin immunoprecipitation (ChIP) II II 
Triglyceride assay Palanker et al. 2009 II 
Glucose and trehalose assay Zhang et al. 2011 I, II 
Glycogen assay Parrou et al. 1997 I 
Cell culture I, II I, II 
Transfection of cells I, II I, II 
Metabolomics I I 
Lipid analysis by mass spectrometry II II 
Agilent Drosophila gene expression microarray I I 
Illumina RNA sequencing II II 
Gene enrichment analysis II II 
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4. RESULTS  
4.1. Mondo-Mlx is essential for dietary sugar 
tolerance in Drosophila (I) 
4.1.1. Loss of mlx leads to late pupal lethality in 
Drosophila  
To study the function of Drosophila Mondo-Mlx, 
we first created an mlx null mutant fly via imprecise 
excision of a P-element (P[XP]bigmaxd07258). The 
mlx1 mutant allele lacks the entire coding region of 
the mlx gene and 17 C-terminal amino acids of the 
neighbouring gene CG3368. Lines where the P-
element was precisely excised were recovered to 
serve as controls. We generated a polyclonal 
antibody against Mlx and confirmed the complete 
absence of Mlx protein by Western blot from 3rd 
instar larvae. Also the mRNA expression, measured 
by qRT-PCR, was lost in the mlx null mutant 
animals. The loss of mlx led to pupal lethality, with 
only very few animals able to emerge as adult flies. 
 
In mammals, Mlx acts as a heterodimeric pair of 
two Mondo paralogs, ChREBP and MondoA, 
whereas Drosophila genome encodes a single 
mondo orthologue. We demonstrated with co-
immunoprecipitation in Drosophila S2 cells that 
Mlx biochemically interacts with Mondo, 
suggesting that the heterodimeric function is 
conserved in the fly. 
4.1.2. Mondo-Mlx deficient animals show 
intolerance to dietary sugars 
On our standard laboratory food, mlx1 mutant 
animals displayed a one-day delay in pupation and 
late pupal (pharate) lethality. Interestingly, we 
found that the delay in pupation displayed 
significant variation between the so-called 
“standard laboratory diets”. Since the mammalian 
ChREBP/MondoA-Mlx had been identified as a 
sugar responsive transcription factor, we 
hypothesized that the dietary component 
responsible for the observed differences in 
developmental delay would be the amount of 
carbohydrates.  
 
To test this, we prepared a minimal diet rich in 
protein (20% baker’s yeast (w/v) in PBS + 0.5% 
agarose and 2.5% Nipagin as a preservative) with 
increasing amounts of sucrose (5-20% w/v). 
Whereas the mlx1 mutants developed with similar 
kinetics as control animals on 20% yeast only food, 
adding sucrose into the diet gradually slowed down 
their development. With 20% yeast + 15% sucrose 
diet that still sustained normal development of 
control animals, virtually all of the mlx1 mutant 
larvae failed to pupate. Furthermore, the mutants 
were unable to survive on a 20% sucrose only diet.  
 
To confirm that the sugar sensitive phenotype was 
due to loss of Mondo-Mlx function, we used RNAi-
mediated knockdown of mlx and mondo. 
Ubiquitous knockdown of both mondo and mlx led 
to decreased adult emergence and increased pupal 
lethality on high sugar diet, respectively. The sugar 
sensitivity of mondo knockdown was enhanced by 
removing one copy of mlx, providing further 
genetic support for joint function and evolutionary 
conservation of the system. Moreover, sugar 
intolerance and pupal lethality were rescued by 
ubiquitous expression of transgenic mlx.  
4.1.3. Loss of Mondo-Mlx leads to severe 
metabolic defects in vivo 
The severe intolerance toward dietary sugars 
prompted us to study in detail the metabolic 
phenotypes of mlx1 mutants. We measured the 
circulating glucose levels from the haemolymph 
and found that already on the yeast only diet, the 
mlx1 mutants displayed significantly higher 
circulating glucose levels. The hyperglycaemic 
phenotype became more severe by adding only 5% 
of sucrose into the diet. We also measured the levels 
of the circulating trehalose. Trehalose is composed 
of two glucose molecules and it is the main form of 
circulating sugar in insects (Becker et al. 1996). 
Circulating trehalose levels were also significantly 
higher in the mlx1 mutants, both on yeast only and 
20% yeast +5% sucrose diets. To rule out the 
possibility that the neighbouring gene CG3368 
would play a role in the phenotypes observed in the 
mlx1 mutants, we performed a series of in vivo 
knockdown studies with CG3368. Knockdown of 
CG3368 had no influence on sugar tolerance, 
circulating glucose or trehalose levels. 
 
To get a comprehensive view of the metabolic 
profile of the mlx1 mutants, we performed a 
lipidomics analysis with mass spectrometry, in 
collaboration with Dr. Matej Oresic and Dr. Tuulia 
Hyötyläinen in VTT Otaniemi. The analysis 
revealed significant changes especially in lipid and 
phospholipid metabolism. Phospholipids such as 
phosphatidylethanolamine and 
lysophosphatidylcholine were significantly 
downregulated in the mlx1 mutants. The total 
triglyceride levels also showed a lower trend in the 
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mlx1 mutants, although the difference to control was 
not statistically significant. Interestingly, the profile 
of triglyceride species was remarkably altered. The 
mlx1 mutants showed strong enrichment in 
triglyceride species with long fatty acid tails. In 
addition, the ceramide levels were strongly elevated, 
suggesting that the mlx1 mutants might suffer from 
lipotoxicity. The mlx1 mutants also showed a 
dramatic increase in urea levels, whereas the total 
amino acid levels were significantly downregulated, 
suggesting that the mutants are unable to utilize 
sugars and therefore catabolize amino acids as their 
energy. 
4.1.4. Mondo and mlx are expressed in the 
metabolic tissues of Drosophila 
In mammals, the two Mondo paralogs MondoA and 
ChREBP are both ubiquitously expressed, however 
MondoA is predominantly expressed in skeletal 
muscles whereas the highest expression of ChREBP 
is found in the liver and adipose tissue (Billin et al. 
2000; Yamashita et al. 2001; Iizuka et al. 2004). 
The gene duplication event that took place before 
or during vertebrate evolution most likely 
contributed to the existence of two Mondo proteins 
in mammals (McFerrin and Atchley 2011). It is 
possible that during the course of evolution, the 
functions of the ancient Mondo protein were 
divided between MondoA and ChREBP leading to 
two distinct glucose-responsive pathways operating 
in different tissues in a similar fashion.  
 
To identify the most critical tissues for Drosophila 
Mondo-Mlx function, we first analysed their gene 
expression using qPCR. Expression of mondo and 
mlx mRNA showed spatial correlation, being 
highest in the fat body, gut and renal tubules 
(Malpighian tubules). Next we utilized the UAS-
GAL4 system to rescue mlx expression tissue 
specifically in the mlx1 mutant background. As 
expected, restoring mlx expression ubiquitously 
with tub-Gal4 rescued both the viability and sugar-
sensitivity of mlx1 mutants. While restoring mlx 
expression in neurons (Elav-GAL4) or muscle 
(Mef2-GAL4) did not improve the mutant 
phenotype, ectopic expression of mlx in the fat body 
(Ppl-GAL4, Cg-GAL4, r4-GAL4) rescued both 
viability and sugar-sensitivity. This implies that fat 
body, which is functionally equivalent to 
mammalian liver and adipose tissue, is the most 
critical tissue for Mondo-Mlx function. 
4.2. Identification of putative Mondo-Mlx target 
genes by Agilent gene expression analysis (I) 
In order to identify the downstream targets of 
Mondo-Mlx responsible for the mutant phenotypes, 
we performed Agilent gene expression microarrays 
specifically from the fat bodies of 3rd instar control 
and mlx1 mutant larvae kept on 20% yeast vs. 20% 
yeast + 5% sucrose diets. Comparison of gene 
expression profiles between the different diets did 
not show any significant changes in control or mlx1 
mutants, suggesting that addition of 5% sucrose to 
the diet does not have any long-term physiological 
effects, at least at the transcriptional level. However, 
the comparison between control and mlx1 mutants 
on the 20% yeast + 5% sucrose diet revealed 
significant changes in a number of genes (>100 
with >2-fold change and adjusted p-value<0.05), 
most of them having a role in different metabolic 
processes. As expected, mlx was the most 
downregulated gene in the microarray. We did a 
Gene Set Enrichment Analysis (GSEA) to identify 
the pathways and processes affected by loss of mlx, 
and found that glycolysis, fatty acid metabolism 
and nitrogen metabolism (KEGG categories) were 
strongly downregulated in the mlx1 mutants. 
 
Among the most downregulated genes in the mlx1 
mutants were the 3-hydroxybutyrate 
dehydrogenase shroud (sro, CG12068), 
phosphoserine phosphatase astray (aay, CG3705), 
glycerol-3-phosphate dehydrogenase (Gpdh, 
CG9042), stearoyl-CoA desaturase desaturase 1 
(Desat1, CG5887), aldehyde dehydrogenase type 
III (Aldh-III, CG11140), glutamine synthetase 1 
(Gs1, CG2718) and amylase proximal (Amy-p, 
CG18730). Interestingly, one of the most strongly 
downregulated genes in mlx1 mutant fat body was 
the Krüppel-like transcription factor cabut (cbt, 
CG4427), suggesting that Mondo-Mlx regulates its 
downstream targets at least in part through 
secondary transcriptional effectors.  
 
We also looked at the homologues of known 
mammalian ChREBP/MondoA-Mlx targets in our 
microarray data and found that the expression 
levels of fatty acid synthase (FAS, CG3523), acetyl-
CoA carboxylase (ACC, CG11198) and 
phosphofructokinase 2 (PFK2, 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase, CG3400) were 
all downregulated in mlx1 mutant fat bodies, 
however they did not pass our significance cut-offs.   
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4.3. Sugar intolerance and hyperglycaemia are 
phenotypes that can be genetically uncoupled (I) 
To test whether any of the downregulated genes 
would explain the mlx1 mutant phenotypes, we 
carried out a systematic in vivo sugar sensitivity 
RNAi screen for >100 genes downregulated in the 
mlx1 mutants. We also included in the screen a 
selected set of genes that are known targets of the 
mammalian ChREBP/MondoA-Mlx, but did not 
pass our strict cut-offs. 
 
We used the Vienna Drosophila Research Centre 
RNAi line collection for the screen, in which we 
crossed the lines with a ubiquitous tub-GAL4 driver, 
collected the 1st instar larvae into 20% yeast (low 
sugar diet) and 20% yeast + 15% sucrose (high 
sugar diet) diets and scored for pupation and 
hatching kinetics. Out of the 105 lines tested, 6 
showed embryonic lethality, 21 died during the 
larval stage and 16 resulted in pupal lethal 
phenotype, while 59 had no apparent diet-
dependent phenotype. Four lines showed a diet-
dependent developmental phenotype. Knockdown 
of cabut, Aldh-III and PFK2 phenocopied the 
sugar-sensitive phenotype of mlx1 mutant animals, 
whereas knockdown of FAS led to a reverse 
phenotype where the larvae displayed significantly 
lower survival into the pupal stage on the 20% yeast 
diet compared to the 20% yeast + 15% sucrose diet.  
 
Knockdown of the transcription factor cabut and 
PFK2 led to a dramatic sugar-sensitive phenotype, 
with only few animals able to reach the pupal stage 
on high sugar diet. The knockdown of Aldh-III also 
led to late pupal (pharate) lethality on low sugar diet, 
to a lower pupation rate on high sugar diet, earlier 
pupal lethality, and also to a lower larval survival 
rate on the 20% sucrose only diet. Importantly, 
restoring the Aldh-III expression in the mlx1 mutant 
background improved the larval survival on the 20 
% sucrose only diet. However, ectopic expression 
of Aldh-III did not rescue the mlx1 mutant survival 
on the high sugar diet, suggesting that additional 
downstream targets contribute to the complex 
metabolic phenotype of mlx1 mutants.  
 
In addition to the dietary sugar-intolerance, the mlx1 
mutants display high circulating glucose levels. 
Surprisingly, only the knockdown of PFK2 
phenocopied the hyperglycaemic phenotype, while 
loss of Aldh-III or cabut did not have any 
significant effect on the circulating glucose levels. 
The dietary sugar intolerance and circulating 
glucose levels are phenotypes that can thus be 
genetically uncoupled.  
4.4. Sugar-induced transcription in Drosophila 
melanogaster (II) 
4.4.1. Mondo-Mlx regulates the majority of 
sugar-induced transcription 
Our Agilent gene expression analysis provided us 
with a number of putative Mondo-Mlx targets, 
however we were surprised to find no effect 
between the yeast and yeast + 5% sucrose diets at 
the level of gene expression. Mondo-Mlx is 
activated by intracellular glucose, and thus we 
hypothesized that in our experimental setting, the 
long exposure to moderate sugar levels led to 
metabolic and transcriptional adaptations. The 
mammalian in vitro data shows that 
ChREBP/MondoA-Mlx is very rapidly translocated 
to the nucleus after glucose intake (Kawaguchi et al. 
2001; Stoltzman et al. 2008). Also, the 
transcriptional responses to sugar feeding in flies 
are known to occur extremely fast (Zinke et al. 
2002), suggesting that a more dynamic 
experimental approach is needed to define the 
sugar-induced transcriptome and the role of 
ChREBP/Mondo-Mlx in the process. In addition, 
the mammalian studies on identifying target genes 
of the mammalian ChREBP/MondoA-Mlx have 
largely focused on specific cell types (Ma et al. 
2006; Jeong et al. 2011), and whereas our 
microarray was done from the fat bodies, the tissue-
specific expression profile of Mondo-Mlx suggests 
a broader role for its function.  
 
These observations, together with the improved 
feasibility of next generation sequencing 
techniques, prompted us to perform an Illumina 
RNAseq gene expression profiling of whole larvae. 
The animals were first kept on a low-sugar diet and 
subsequently transferred either to low (10% yeast) 
or high-sugar diets (10% yeast + 20% sucrose) for 
8 hours, followed by total RNA extraction. We 
chose the 8h time point based on the expression 
kinetics of FAS and sugarbabe, two genes known 
to be regulated by dietary sugars (Zinke et al. 2002). 
Both the expression of FAS and sugarbabe peaked 
at 8h after sugar-feeding, and therefore we chose 
this time point for our genome-wide analysis. 
Furthermore, we used food coloured with blue dye 
to confirm that the animals to be analysed had 
indeed eaten. 
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First we looked at the sugar-regulated 
transcriptome in control animals, and found that 
dietary sugar is regulating multiple metabolic 
processes at the transcriptional level. As expected, 
among the most highly upregulated processes in 
response to high-sugar diet were glycolysis, 
gluconeogenesis, pentose phosphate pathway, 
pyruvate metabolism and fatty acid biosynthesis. In 
contrast, valine, leucine and isoleucine degradation 
and ribosome biogenesis were significantly 
downregulated in response to sugar feeding. 
 
Previous studies on cultured mammalian cells have 
shown that Mlx together with ChREBP or MondoA 
plays a key role in sugar-regulated transcription 
(Ma et al. 2006; Sans et al. 2006; Stoltzman et al. 
2008; Jeong et al. 2011). Therefore, we wanted to 
determine which part of sugar-induced 
transcription is regulated in an Mlx-dependent 
manner in the context of the whole organism. To do 
this, we compared the sugar-induced 
transcriptomes of control and mlx1 mutant animals. 
In agreement with the mammalian data, we found 
that of the most strongly (logFC>2) sugar 
upregulated genes ~60% were significantly 
downregulated in mlx1 mutants, confirming a key 
role for Mondo-Mlx as the main transcriptional 
activator in response to dietary sugars also in flies. 
However, the sugar downregulated-mlx1 
upregulated group (47% dependent on Mlx with 
logFC<-2) also contained a number of important 
metabolic regulators such as amylases, lipases and 
trehalase, suggesting that Mondo-Mlx plays a 
crucial role in both sugar induced and sugar 
attenuated gene expression. 
 
We further looked at the sugar-regulated/Mlx-
dependent processes, and found that of the 
upregulated processes, those most highly Mlx-
dependent were glycolysis, gluconeogenesis, 
pentose phosphate pathway, pyruvate metabolism, 
glutathione metabolism and the cytochrome p450 
genes. Of the downregulated processes, valine, 
leucine and isoleucine degradation and fatty acid 
metabolism were most highly dependent on Mlx. 
 
The mammalian ChREBP/MondoA-Mlx 
recognizes ChoREs in the promoter regions of their 
target genes to which they bind as heterotetramers 
to activate transcription. In order to assess which 
part of the sugar-regulated genes are direct targets 
of Mondo-Mlx, we looked at putative ChoREs in 
the promoters of sugar regulated/Mlx-dependent set 
of genes. Putative ChoREs were significantly 
enriched in the sugar-upregulated but not in the 
sugar-downregulated group, further confirming the 
role of Mondo-Mlx as a transcriptional activator, 
and suggesting that the down-regulated genes are 
indirect targets of Mondo-Mlx. 
4.4.2. Mondo-Mlx is a key regulator of glycolysis 
and lipogenesis 
The mammalian ChREBP/MondoA has been 
characterized as a key regulator of glycolysis and 
lipogenesis (Ishii et al. 2004; Ma et al. 2005; Ma et 
al. 2006; Sans et al. 2006; Jeong et al. 2011), which 
was confirmed by our RNAseq data. The glycolytic 
target genes of the mammalian ChREBP/MondoA-
Mlx include HKII, PFKFB3 and L-PK (Sans et al. 
2006; Ma et. al. 2005; Ishii et al. 2004; Jeong et al. 
2011). Our data however suggest an even broader 
role for Mondo-Mlx in regulating the glycolytic 
flux. We found that the genes encoding 
phosphoglucose isomerase (Pgi, CG8251), 
aldolase (Ald, CG6058), enolase (Eno, CG17654), 
pyruvate kinase (PyK, CG7070), several members 
of the pyruvate dehydrogenase complex (CG11876, 
CG5261, CG7430, l(1)G0334) and the acetyl 
Coenzyme A synthase (AcCoAS, CG9390) were 
strongly induced upon sugar feeding in control 
animals, but not in the mlx1 mutants. 
 
Perhaps the best characterized role of ChREBP-
Mlx is the regulation of de novo lipogenic enzymes 
FAS and ACC in response to glucose stimulus.  In 
addition to the previously known lipogenic targets 
FAS, ACC, acetyl-CoA synthetase (ACS/AcCoAS), 
ATP citrate lyase (ACL/ATPCL) and Desat1, we 
found that Mondo-Mlx also regulates many other 
aspects of lipid metabolism. For instance, we found 
that Mlx regulates the sugar-induced lipid storage 
and breakdown through the transcriptional control 
of perilipins, lipases and several genes of the beta-
oxidation pathway.   
4.4.3. Novel roles for Mondo-Mlx in the 
regulation of carbohydrate transport and 
digestion in response to sugar-feeding 
Intriguingly, our RNAseq data revealed a number 
of new putative targets for Mondo-Mlx, many of 
them presenting completely new metabolic 
pathways potentially regulated by sugar feeding 
and Mondo-Mlx. One of the first metabolic 
phenotypes we identified in the mlx1 mutants were 
the elevated circulating glucose levels. Whereas our 
microarray analysis did not reveal any obvious 
candidate target genes responsible of the 
hyperglycaemic phenotype, the RNAseq data 
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revealed that the expression of several putative 
sugar transporters was regulated by sugar-feeding 
in an Mlx-dependent manner. Hemolymph glucose 
can be regulated both at the level of glucose uptake 
in the gut as well as by excretion through the renal 
(Malpighian) tubules. Furthermore, our tissue-
specific gene expression analyses by qPCR showed 
that many of these transporters were expressed 
tissue-specifically in response to sugar feeding and 
that this induction was dependent on Mondo-Mlx. 
We found that the sugar-induced expression of the 
putative sugar transporters CG7882 and CG15406 
were highly specific to renal tubules, whereas 
CG4797 and CG4607 showed specificity to the gut.  
 
The Drosophila genome encodes three α-amylases, 
enzymes that are needed to breakdown dietary 
starch. The expression of α-amylases is known to 
be repressed by dietary sugars (Benkel and Hickey 
1987), and our data showed that this sugar-induced 
repression was highly dependent on Mondo-Mlx. 
The absence of ChoREs in the promoters of α-
amylases, and the growing evidence of Mondo-Mlx 
acting only as a transcriptional activator, suggest 
that the transcriptional control of α-amylases is 
regulated by a secondary effector downstream of 
Mondo-Mlx.  
4.4.4. Transcriptional activation of the pentose 
phosphate pathway is essential for growth on 
high sugar diet 
One of the most strongly sugar upregulated/Mlx-
dependent processes was the pentose phosphate 
pathway (PPP). Glucose-6-phosphate 
dehydrogenase (G6PDH), the gatekeeper enzyme 
for PPP, is a known target of mammalian ChREBP-
Mlx (Ma et al. 2006). Its Drosophila orthologue 
Zwischenferment (Zw), is upregulated after sugar 
feeding of Drosophila larvae through an unknown 
mechanism (Zinke et al. 2002). Surprisingly we 
found that in addition to Zw, Mondo-Mlx regulates 
virtually every step of the PPP in response to sugar. 
The expression of 6-phosphogluconolactonase 
(CG17333), 6-phosphogluconate dehydrogenase 
(Pgd, CG3724), transaldolase (Tal, CG2827), 
ribose-5-phosphate isomerase (Rpi, CG30410) and 
transketolase (CG8036), all displayed strong Mlx-
dependent upregulation upon sugar feeding. 
 
Moreover, the knockdown of Zw in vivo led to 
severely impaired growth on high-sugar diet, 
demonstrating for the first time the physiological 
importance of the PPP activation in the presence of 
sugar. Since the NADPH produced by the oxidative 
phase of PPP is needed for DNL, we hypothesized 
that inhibition of PPP might hamper triglyceride 
accumulation in response to sugar feeding. This 
was exactly the case, and the total TAG content of 
Zw knockdown larvae was significantly lower 
compared to the control. 
4.4.5 Regulation of the biosynthesis of non-
essential amino acids glutamine and serine by 
Mondo-Mlx 
Interestingly, our analysis uncovered previously 
unknown roles for Mondo-Mlx in the control of 
amino acid metabolism. Several genes involved in 
glutamine and serine biosynthesis were induced by 
dietary sugars in an Mlx-dependent manner. The 
non-essential amino acids glutamate and glutamine 
play a central role in amino acid and energy 
metabolism (DeBerardinis and Cheng 2010). 
Functional analysis of the putative Mondo-Mlx-
targets revealed that knockdown of Glutamine 
synthetase 2 (Gs2, CG1743) led to impaired growth 
on high-sugar diet in vivo.   
 
Regulation of serine metabolism is important for 
the biosynthetic capacity of cells through so-called 
one carbon metabolism pathway. The main routes 
for serine biosynthesis are through 3-
phosphoglycerate, an intermediate of glycolysis, or 
through glycine. The rate-limiting enzyme in the 
glycolytic route of serine biosynthesis, the 
phosphoserine phosphatase astray, was upregulated 
by sugar in an Mlx-dependent manner. Also the 
knockdown of astray led to a growth defect on high 
sugar diet, indicating that the biosynthesis of the 
non-essential amino acids glutamine and serine 
must be coordinated with respect to sugar intake to 
sustain optimal growth, and that Mondo-Mlx is a 
key regulator of these process. 
4.5. Mondo-Mlx governs a secondary tier of 
transcriptional effectors (II) 
In our microarray study, we found the transcription 
factor cabut to be among the most highly Mlx-
regulated genes. This finding was confirmed by the 
sugar-induced transcriptome data where cabut was 
found to be the most highly Mlx-dependent sugar 
regulated gene. Krüppel-like factor Klf10, the 
closest mammalian homologue of cabut along with 
Klf11, has been shown to be a target of mammalian 
ChREBP-Mlx (Iizuka et al. 2011), and it has been 
associated with the development of type 2 diabetes 
(Gutierrez-Aguilar et al. 2007). A parallel study in 
our group examined further the role of Cabut in 
sugar sensing, and found that it is a direct target of 
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Mondo-Mlx, acting as a transcriptional repressor, 
inhibiting the expression of phosphoenolpyruvate 
carboxykinase (Pepck, CG17725) (Bartok et al. 
2015). This study also showed that the deregulation 
of Pepck in the mlx1 mutants is the underlying 
reason for the imbalance between glycerol and 
glucose metabolism, and also causes 
developmental lethality (Bartok et al. 2015).  
 
In addition to cabut, the RNAseq data revealed a 
number of other transcriptional effectors that were 
regulated by Mlx. Sugarbabe (sug, CG3850, Glis 
family), clockwork orange (cwo, CG17100, 
BHLHE40/41), kahuli (Kah, CG17181, 
Snail/Scratch family), grain (grn, CG9656, GATA-
type), hormone receptor-like in 96 (Hr96, 
CG11783, nuclear receptor subfamily, LXR) and 
seven up (svp, CG11502, nuclear receptor 
subfamily, NR2F2/COUP-TFII), all displayed 
Mlx-dependent expression after sugar feeding.  
 
Previous studies in flies have shown that sugarbabe 
is one of the earliest genes induced by sugar and 
that its expression is one of the highest among 
sugar-regulated genes, however its function has 
remained largely elusive (Zinke et al. 2002). The 
closest mammalian homologue of Sugarbabe is the 
Gli-similar transcription factor 2 (GLIS2). The 
GLI-similar family (GLIS1-3) of transcription 
factors belong to the Krüppel-like family of zinc 
finger proteins, and they have been shown to have 
a critical role in kidney development (Kim et al. 
2008b). Dysfunction of GLIS proteins has been 
associated various human diseases, including the 
development of diabetes, cystic kidney disease and 
cancer (Lichti-Kaiser et al. 2012). Furthermore, 
similar to Myc, GLIS1 has been shown to greatly 
enhance the reprogramming of somatic cells into 
induced pluripotent stem cells (iPSCs), forming the 
famous cocktail of four transcription factors 
including Oct3/4, Sox2 and Klf4, required for the 
generation of iPSCs (Maekawa et al. 2011). 
4.5.1. Sugarbabe and Dawdle are direct targets 
of Mondo-Mlx and required for organismal 
sugar tolerance 
We studied further the role of Sugarbabe in vivo in 
Drosophila and found that knockdown of 
sugarbabe leads to impaired growth on high-sugar 
diet. We also created a deletion mutant of 
sugarbabe, which displayed a similar sugar-
sensitive phenotype, further confirming its role in 
dietary sugar tolerance.  
 
In addition to sugarbabe, the Activin ligand dawdle 
was among the sugar up-regulated/Mlx-dependent 
group of genes. Dawdle had been recently 
identified as a sugar induced gene in Drosophila, 
but the underlying upstream regulatory mechanism 
had remained unknown (Chng et al. 2014). Loss of 
Activin signalling has been also associated with a 
nutrient-dependent phenotype in Drosophila, 
where the dawdle null larvae grown on a high 
protein diet showed a striking growth advantage 
compared to larvae grown on standard laboratory 
diet (Ghosh and O'Connor 2014). We found that the 
knockdown of dawdle leads to severe diet-
dependent phenotype – on high sugar diet the 
dawdle RNAi animals die at the late pupal stage, 
whereas on low sugar diet they reach adulthood.  
 
This led us to ask how Mondo-Mlx, Sugarbabe and 
Dawdle are connected at the regulatory level. We 
first showed that both sugarbabe and dawdle are 
direct targets of Mondo-Mlx both by in vitro and in 
vivo ChIP analysis. Furthermore, we found that 
while dawdle expression was independent of 
Sugarbabe, the expression of sugarbabe was 
strongly dependent on Dawdle, suggesting that 
Sugarbabe acts downstream of Activin signalling. 
4.5.2. Sugarbabe regulates a subset of Mondo-
Mlx targets 
Next we wanted to study in more detail the role of 
Sugarbabe in sugar-induced transcription. To do 
this, we performed a similar sugar-induction 
experiment with sugarbabe mutants as described 
for mlx1 mutants, followed by RNA sequencing. 
The sugar-regulated gene sets dependent on 
Sugarbabe displayed significant overlap with Mlx-
dependent genes, including astray, the enzyme that 
catalyses the last step in the biosynthesis of serine 
from carbohydrates. The knockdown of dawdle 
also suppressed the sugar-induced expression of 
astray, further confirming the finding that the 
Activin-Sugarbabe regulatory axis functions 
downstream of Mondo-Mlx. 
 
The sugar-induced/Sugarbabe-dependent group of 
genes included also α-amylases. Furthermore, we 
found that larvae overexpressing sugarbabe survive 
poorly on a diet with high starch content compared 
to control animals, providing evidence for 
functional importance of Sugarbabe-mediated 
regulation of amylase proximal. Moreover, it has 
been previously demonstrated that Activin 
signaling is required for the sugar-mediated 
repression of α-amylases (Chng et al. 2014). 
? 46 
Together, these results indicate that Mondo-Mlx 
suppresses starch breakdown on high sugar diet 
through its downstream effectors Dawdle and 
Sugarbabe.  
 
Of the sugar-induced/Sugarbabe-dependent 
processes, fatty acid biosynthesis was among the 
most strongly enriched. To test whether Sugarbabe 
activity on lipogenic genes FAS and ACC is 
dependent on Mondo-Mlx, we rescued sugarbabe 
expression in the fat bodies of mlx1 mutants. Indeed, 
the ectopic expression of sugarbabe was sufficient 
to rescue both the expression of FAS and ACC, and 
the triglyceride levels of mlx1 mutant animals. Thus, 
Sugarbabe is acting downstream of Mondo-Mlx 
also as a feed-forward regulator of lipogenesis. We 
also found that FAS and ACC levels were reduced 
in dawdle RNAi animals, providing further support 
for our model in which Mondo-Mlx is acting as a 
master regulator of transcriptional network 
composed of several secondary targets, including 
Sugarbabe, which is also acting downstream of 
TGF-β/Activin signalling. 
4.6. Human homologs of Mondo-Mlx targets are 
enriched among triglyceride-associated variants 
(II) 
Finally, we compared our RNAseq data on existing 
human GWAS studies on circulating triglycerides, 
a phenotype associated with human ChREBP 
(MLXIPL) polymorphism (15). We found a striking 
correlation with putative Mondo-Mlx targets and 
human genomic variants associated with circulating 
triglyceride levels (ENGAGE Consortium study, 
(Surakka et al. 2015)). Moreover, we found that for 
some of the loci, the actual causal genes underlying 
the metabolic phenotypes could be predicted based 
on our data. In conclusion, our data suggest that the 
data on Drosophila Mondo-Mlx targets can be used 
to predict putative causal genes in the vicinity of the 
triglyceride-associated genomic variants in humans. 
×   
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5. CONCLUSIONS AND FUTURE 
PERSPECTIVES 
5.1. Mondo-Mlx is a master regulator of a 
sugar-induced gene regulatory network  
In this thesis I have characterized the in vivo roles 
of Drosophila Mondo-Mlx in sugar-induced 
transcription. One of the first and major findings 
was that the loss of functional Mondo-Mlx leads to 
dietary sugar intolerance in vivo. To our knowledge, 
this is a phenotype that has never been reported in 
the fly before. Most importantly, this phenotype 
resembles the one of ChREBP-/- mice that are also 
intolerant to dietary carbohydrates (Iizuka et al. 
2004), demonstrating the functional conservation 
of ChREBP/Mondo-Mlx across phyla. The 
RNAseq analysis of Drosophila Mondo-Mlx target 
genes further confirmed the conservation at the 
level of target gene regulation, including for 
example the well-established mammalian 
ChREBP-Mlx targets FAS, ACC and G6PDH. 
Moreover, our study that utilized a transient sugar 
exposure in vivo, was the most comprehensive 
sugar-induced transcriptome profiling performed in 
a physiological setting so far. The mammalian 
ChREBP/MondoA-Mlx are best known for their 
roles in regulating glycolysis and lipogenesis. 
However, other metabolic pathways and 
downstream effectors have also been indicated as 
their targets, including Krüppel-like factor 10 and 
DEC1. This thesis further broadened the view of 
ChREBP/MondoA-Mlx as a metabolic regulator, 
extending its role in Drosophila also to for example 
amino acid metabolism.  
 
One of the genes most prominently regulated by 
sugar and Mondo-Mlx in our study was the Gli-
similar transcription factor sugarbabe. Although 
sugarbabe had been identified as the earliest and 
strongest sugar-responsive gene in Drosophila 
more than 10 years ago, data on its role in regulating 
glucose metabolism had remained limited. A 
suppressive role for Sugarbabe in regulating the 
repression of lipolytic genes before the activation 
of lipogenic genes was suggested by Zinke and 
colleagues, who proposed in 2002 that: “Based on 
these observations, we propose a model in which an 
as yet unknown transcription factor(s) is activated 
by a sugar signal. This factor(s) then activates sug, 
as well as a set of genes involved in fatty acid 
synthesis, such as acetyl CoA carboxylase and ATP 
citrate lyase” (Zinke et al. 2002). This prediction 
turned out the be accurate, and we and others have 
now identified many of the missing links in the 
proposed model (Figure 13).  
 
We found that sugarbabe is a direct target of 
Mondo-Mlx, and that it regulates fatty acid 
synthesis downstream of Mondo-Mlx by inducing 
the expression of lipogenic genes ACC, FAS, 
Figure 13. The sugar-induced gene regulatory network 
Left: In the model proposed by Zinke et al. 2002, a sugar signal activates a transcription factor(s) that activates 
lipogenesis and the transcription factor Sugarbabe, which represses the expression of lipases in response to sugars. 
Right: The model proposed in this thesis: The sugar-activated Mondo-Mlx activates directly the expression of many 
enzymes involved in variety of metabolic processes, including lipogenesis, lipid storage, lipolysis, β-oxidation, glucose 
uptake, glycolysis, pentose phosphate pathway, starch digestion, serine biosynthesis, and glutamine and glutamate 
uptake and biosynthesis. In addition, Mondo-Mlx induces the expression of secondary effectors that mediate part of its 
functions in response to sugars. These effectors include Sugarbabe, Cabut, Clockwork orange, Seven up and Hormone 
receptor-like in 96. 
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AcCoAS and ATPCL in response to sugar feeding. 
Furthermore, our RNAseq analysis of the 
sugarbabe mutants revealed that the expression of 
CG6271, a lipase that is repressed in response to 
sugar, was also strongly upregulated in mutants, 
supporting the findings and model proposed by 
Zinke et al. In addition, we found that Sugarbabe is 
regulating the repression of α-amylases. Amylase 
repression is also inhibited in the mlx1 mutants, and 
thus we propose a model in which Sugarbabe is 
mediating the sugar/Mondo-Mlx-dependent 
repression of α-amylases. Gli-similar transcription 
factor 2, the human homologue of Sugarbabe, was 
originally identified as a bifunctional transcription 
factor, regulating both the activation and repression 
of its target genes involved in kidney development 
(Zhang et al. 2002). Interestingly, variants of 
another member of the GLIS-family, GLIS3, are 
now established as one of the strongest known 
genetic risk factors for both type 1 and type 2 
diabetes (Yang and Chan 2016). GLIS3 is a key 
regulator of both the expression of insulin and 
proliferation of β-cells (Kang et al. 2009; Yang et 
al. 2009; Yang et al. 2013; ZeRuth et al. 2013). 
According to FlyBase, the closest homologue of 
GLIS3 in Drosophila is a gene called lame duck 
(CG4677). However, Lame duck is a regulator of 
myogenesis, and we found the expression of lame 
duck to be only moderately induced by dietary 
sugars. In fact, sugarbabe is expressed in the IPCs 
where it regulates the expression of dILPs 
(Varghese and Cohen 2007), suggesting that it 
might be the functional homologue of GLIS3.  
  
However, as with any model, answers give rise to 
new questions, and the major future challenges 
include resolving the roles of other transcriptional 
effectors downstream of sugar signals and Mondo-
Mlx. In addition to sugarbabe, our RNAseq 
profiling revealed a number of other transcriptional 
regulators regulated by sugar in a Mondo-Mlx 
dependent manner, including cabut, clockwork 
orange, seven up and hormone receptor-like in 96. 
 
The human homologues of cabut (KLF10) and 
clockwork orange (BHLHE40/41, DEC1/2) are also 
known targets of mammalian ChREBP-Mlx. 
KLF10 and DEC1/DEC2 are both involved in the 
regulation of the circadian clock, a molecular 
system stimulated by periodic environmental 
stimuli that regulates the sleep-wake cycle, feeding 
behavior and metabolism. Although the master 
clock is located in the brain, the clock proteins are 
expressed ubiquitously in all tissues. In fact, a large 
number of metabolic genes involved in 
carbohydrate and lipid metabolism are regulated by 
clock proteins (McGinnis and Young 2016). There 
is increasing evidence of a link between the 
dysregulation of the clock and the development of 
metabolic diseases. Mice with mutations in the core 
clock components develop obesity, metabolic 
syndrome and type 2 diabetes (Turek et al. 2005; 
Marcheva et al. 2010). High fat diet in turn disrupts 
the function of the clock, which leads to the 
dysregulation of nuclear receptors and their 
downstream metabolic target genes (Kohsaka et al. 
2007; Barnea et al. 2009). The importance of 
coordinating feeding behavior with the signals from 
the clock is also shown by studies in which 
consumption of food during the biologically 
inactive period results in metabolic dysregulation 
including higher postprandial glucose and Insulin 
levels (Hampton et al. 1996; Mukherji et al. 2015). 
In fact, it is now known that shift workers are at 
higher risk for developing metabolic syndrome, 
type 2 diabetes and coronary heart disease 
(Kawachi et al. 1995; De Bacquer et al. 2009; Pan 
et al. 2011).  
 
KLF10 has been proposed to be the transcription 
factor mediating the information from the clock to 
the level of metabolic gene expression in the liver 
(Guillaumond et al. 2010). Our group has also 
shown that Cabut provides a link between the clock 
and metabolic regulation in response to sugar 
feeding (Bartok et al. 2015). Moreover, the 
mammalian data together with our findings suggest 
that this process is dependent on ChREBP/Mondo-
Mlx (Iizuka et al. 2011; Bartok et al. 2015). 
Interestingly, humans that carry a specific variant 
of the core clock gene CRY1 develop insulin 
resistance, but only if exposed to a high 
carbohydrate diet (Dashti et al. 2014). Taken 
together, the nutritional signals alter the function of 
the clock, but at the same time the dysfunctional 
clock causes metabolic dysregulation, suggesting 
that any alteration in this system can cause a 
feedforward effect, resulting in metabolic disease. 
ChREBP/Mondo-Mlx is likely to play a critical role 
in this process, but the exact mechanisms remain to 
discovered.  
 
The expression of the human homologue of seven 
up, called chicken ovalbumin upstream promoter 
transcription factor II (COUP-TFII), is suppressed 
by sugar in an ChREBP-Mlx dependent manner 
(Perilhou et al. 2008). COUP-TFII has been also 
shown to bind same promoters as ChREBP, 
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including the L-PK promoter, suggesting that 
COUP-TFII and ChREBP might coordinate their 
target gene regulation in response to different 
nutritional signals (Lou et al. 1999). COUP-TFII 
was originally characterized as a gene involved in 
developmental processes, and the null mutant mice 
are embryonic lethal (Pereira et al. 1999; Bardoux 
et al. 2005). COUP-TFII was later shown to play an 
important role in metabolism; heterozygous mice 
are insulin resistant and display abnormal Insulin 
secretion (Bardoux et al. 2005). We found seven up 
expression to be strongly induced in response to 
dietary sugars, and this induction was dependent on 
Mondo-Mlx. Interestingly, although the expression 
of seven up was induced after 8 hours of sugar 
feeding, expression was actually repressed at a 
shorter time point (1.5h), but not in the mlx1 mutant 
animals (unpublished data). This, together with our 
unpublished observation that ubiquitous 
knockdown of seven up leads to early larval 
lethality, suggests a highly conserved role for Seven 
up/COUP-TFII in regulating development and 
metabolism in response to sugar feeding.  
 
The Hormone receptor-like in 96 (Hr96, DHR96) is 
the functional homologue of mammalian LXR. 
Like its mammalian counterpart, it binds 
cholesterol and regulates cholesterol homeostasis 
(Horner et al. 2009). In addition, is has been shown 
to control the breakdown of dietary fats via its 
downstream target lipase called magro, which is 
also required for proper cholesterol metabolism in 
the gut (Sieber and Thummel 2009; Sieber and 
Thummel 2012). Our data show that Hr96 is 
transcriptionally upregulated in response to dietary 
sugars, and that this induction is dependent on 
Mondo-Mlx. Moreover, the knockdown of both 
Hr96 and seven up was recently shown to lead to 
hyperglycemia (Ugrankar et al. 2015), suggesting 
an important role for both of these nuclear receptors 
in regulating glucose homeostasis.  
 
Taken together, in addition to regulating the 
expression of metabolic enzymes directly, Mondo-
Mlx controls a large gene regulatory network 
composed of multiple downstream effectors. The 
downstream transcriptional effectors play diverse 
roles in various biological processes in addition to 
carbohydrate metabolism, including development, 
circadian rhythm and cholesterol metabolism. 
Many of these effectors also appear to be conserved 
targets of the mammalian ChREBP-Mlx, 
suggesting that sugar sensing is an evolutionarily 
conserved process in multicellular animals. It will 
be of great interest to determine the exact roles of 
the other Mondo-Mlx transcriptional effectors in 
regulating metabolism downstream of Mondo-Mlx. 
Drosophila, with its less complex genome and 
lower redundancy, provides an optimal model to 
study further the roles of the Mondo-Mlx regulated 
transcriptional network.  
5.2. Novel ChREBP isoform, control of feeding 
behavior and communication with other 
nutrient sensors  
After their discovery, ChREBP and MondoA have 
been established as key regulators of sugar-induced 
transcription. The first direct target genes to be 
identified were enzymes of the glycolytic and 
lipogenic pathway. Thus, much attention has been 
directed towards clarifying the role of 
ChREBP/MondoA-Mlx in regulating these 
pathways. However, the classical view of ChREBP 
and MondoA as regulators of only glycolysis and 
lipogenesis greatly underestimates the role of these 
transcription factors in regulating a wide range of 
cellular processes both directly and indirectly via 
their secondary effectors.  
 
Although much effort has been put into the 
identification of the upstream signals regulating 
ChREBP and MondoA activity, many questions 
still remain. For instance, while the activating role 
of G6P is now widely accepted, there is still 
controversy about whether other sugar metabolites 
participate in the activation process. Similarly, 
there is no question about the regulatory role of 
G6P-induced nuclear translocation for ChREBP 
and MondoA activity, but now it is also known that 
additional regulatory steps are needed for the final 
transcriptional activity of the heterodimers. There 
is no clear consensus yet on these events, and it 
seems likely that the posttranslational 
modifications together with co-factors and other 
regulatory events required for the final activation 
are cell and tissue type specific. Many of the current 
studies are conducted in vitro with transformed or 
immortalized cell lines that are known to exhibit 
altered metabolism. In fact, the role of MondoA in 
regulating the metabolism of cancer cells has been 
already established (Wernicke et al. 2012; Carroll 
et al. 2015), and thus studying ChREBP and 
MondoA in non-cancerous cell lines or in vivo is 
likely crucial for understanding their roles and 
regulation in a normal physiological context.   
 
It is also surprising how little is known about the 
communication and interaction between different 
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nutrient sensing pathways. The activation of 
ChREBP and MondoA appears to take place 
independently of Insulin, however a large number 
of their target genes are also regulated by the 
Insulin-activated transcription factor SREBP. Thus 
it is likely that these pathways communicate with 
each other to coordinate the expression of their 
target genes in response to various stimuli. In fact, 
it has been recently shown that SREBP expression 
is induced by glucose via ChREBP-Mlx (Jeong et 
al. 2011, Poungvarin et al. 2015). A number of 
nuclear receptors also regulate the expression of the 
same target genes as ChREBP and SREBP. 
ChREBP has been shown to interact physically and 
regulate the expression of its target genes together 
with for example HNF-4α and PGC-1β (Adamson 
et al. 2006; Chambers et al. 2013). Furthermore, the 
ChREBP promoter harbors known binding sites for 
LXRα/RXRα, TRβ1/RXRα, SREBP and for 
ChREBP itself, suggesting a complex regulatory 
system including feedback loops and signaling 
between several nutrient sensing pathways.   
 
One of the most interesting recent studies 
demonstrated that TOR interacts physically with 
both MondoA and ChREBP (Kaadige et al. 2015). 
The authors show that TOR is competing with Mlx 
for binding of MondoA in the cytoplasm, and thus 
controlling its transcriptional activity. This 
interaction is promoted by increased intracellular 
reactive oxygen species (ROS). The MondoA-Mlx 
target TXNIP increases intracellular ROS levels 
and thus the inhibition of MondoA activity by TOR 
is proposed to serve as a protective feedback loop 
to reduce the expression of TXNIP. Interestingly, 
there seems to be a reciprocal regulation between 
MondoA and TOR, since MondoA-Mlx was found 
to suppresses TORC1 activity in response to 2-DG 
treatment (Kaadige et al. 2015). It has been also 
recently suggested that the C. elegans Myc and 
Mondo-like protein MML-1 is regulating longevity 
by stimulating autophagy via inhibition of TOR 
activity (Nakamura et al. 2016). The authors also 
propose a conserved function for Mondo proteins in 
the inhibition of TOR activity. They found that both 
MondoA and ChREBP stimulated the nuclear 
localization of the TOR signaling inhibitor TFEB 
during amino acid starvation in HeLa cells. 
Together, these recent findings indicate a tight 
communication between Mondo and TOR 
signaling pathways.   
 
The identification of the novel ChREBP-β isoform 
has brought a new player to the complex feedback 
regulatory system of ChREBP. The ChREBP-β 
isoform is activated by the α–isoform and is a 
significantly more potent activator of sugar-
induced transcription (Herman et al. 2012). 
Importantly, it was shown that only the expression 
level of ChREBP-β predicts insulin sensitivity in 
humans (Herman et al. 2012), suggesting that the 
isoforms display distinct functions in the 
pathobiology of human metabolic diseases. The 
newly identified ChREBP-β isoform seems to have 
developed only later in the evolution of tetrapods, 
since fish for example lack this isoform (Singh and 
Irwin 2016). To date, fly studies have not 
distinguished separate functional isoforms of 
Mondo or Mlx. However, according to Flybase 
(R6.12), the D. melanogaster Mondo encodes 11 
different isoforms, which differ mainly by their 5’ 
untranslated region. One isoform (Mondo-RE) also 
lacks the first two exons, and it will therefore be 
interesting to learn whether there are functional 
differences between the Drosophila Mondo 
isoforms. Whether the mammalian MondoA 
encodes differently regulated isoforms also remains 
to be discovered.  
5.3. Systemic regulation of whole-body 
metabolism by Mondo-Mlx 
Whereas much of the focus has been on elucidating 
the mechanisms by which ChREBP/MondoA-Mlx 
activity is regulated, and what their direct targets 
are, less is known about the systemic effects of 
ChREBP/MondoA-Mlx on whole-body 
metabolism. The Activin ligand Dawdle expressed 
and secreted from the fat body was recently found 
to be a hormonal regulator acting in the gut to 
suppress the expression of α-amylases (Chng et al. 
2014). Here we show that sugar-induced expression 
is dependent on Mondo-Mlx, providing evidence 
on Mondo-Mlx as a regulator of hormonal signals 
in response to dietary sugars. 
 
Fibroblast growth factor 21 (FGF21) is a 
hepatokine known to be a direct target of ChREBP-
Mlx (Iizuka et al. 2009a). However, only recently 
has the physiological role of ChREBP- induced 
expression of FGF21 been discovered. Liver-
secreted FGF21 was shown to act directly on the 
hypothalamus to suppress food intake and 
specifically sugar feeding (von Holstein-Rathlou et 
al. 2016). Although the fly does not have a 
homologue for FGF21, Drosophila Mondo has 
been suggested to control feeding behavior. 
Knockdown of mondo specifically in the fat body 
or in the IPCs results in decreased feeding behavior 
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of adult flies (Sassu et al. 2012; Docherty et al. 
2015). It has been also suggested that whereas IPCs 
seem to respond to amino acid signals, circulating 
sugar levels are sensed by the corpora cardiaca that 
secretes AKH, which in turn signals to IPCs to 
release dILP3 (Kim and Neufeld 2015). 
Intriguingly, it was recently shown that loss of 
Mondo in the IPCs leads to an increased expression 
of dILP3, suggesting an autonomous role for 
Mondo-Mlx in regulating feeding behavior in the 
brain (Docherty et al. 2015). It will be also 
interesting to learn whether Mondo-Mlx functions 
in the recently identified group of neurosecretory 
cells that were shown to express diuretic hormone 
44 (Dh44), a human homologue of corticotropin-
releasing hormone (CRH) and to be activated 
specifically by dietary sugars (Dus et al. 2015). 
 
In addition to fat body, we found that mondo and 
mlx are also highly expressed in the gut. The 
expression of Mondo proteins in the gut is 
conserved. In addition to its very prominent 
expression in skeletal muscle, heart, kidney and 
liver, MondoA is also expressed in the colon and 
small intestine (Billin et al. 2000). This is also true 
for ChREBP, which although mainly studied in the 
liver and adipose tissue, shows also strong 
expression in the gut (Yamashita et al. 2001; Iizuka 
et al. 2004). Moreover, although Mlx is a 
ubiquitously expressed protein, its expression in 
mice has been found to be highest in the villi of the 
gut (Meroni et al. 2000). The MML-1/MXL-2 are 
also highly expressed in the C. elegans intestine 
(Cairo et al. 2001; Pickett et al. 2007). Despite these 
early findings, the function of ChREBP/MondoA-
Mlx in the gut is still largely unstudied. We show 
here that Mondo-Mlx regulates the expression of 
gut amylases via the secondary effectors Dawdle 
and Sugarbabe. Furthermore, we found sugarbabe 
to display its highest relative expression in the 
larval gut, suggesting an important role for gut in 
the regulation of metabolic responses to sugar 
feeding.  
 
This is not surprising, since the initial decisions of 
nutrient absorption are made in the intestine, which 
is the major site for nutrient intake. The classical 
view of the gut as a metabolically passive organ, 
only responsible for the expression of digestive 
enzymes and subsequent absorption of nutrients, 
has turned out to be false. The gut is a highly 
complex and dynamic organ that not only serves as 
a site for digestion and absorption, but also 
participates in the regulation of metabolism by 
various means. For example, gut-secreted 
hormones regulate metabolism in other tissues, and 
gut-expressed enzymes dictate the fate of some 
nutrients before they even are absorbed. The gut has 
been shown to participate actively in nutrient 
sensing and metabolism in Drosophila as well 
(Miguel-Aliaga 2012). Recent studies have 
highlighted the importance of gut microbiota in 
human health and disease (Cho and Blaser 2012; 
Boulange et al. 2016), and also support the notion 
of the gut as a key organ regulating whole-body 
metabolic homeostasis. The role of ChREBP and 
MondoA in these processes, and whether there is 
interaction between the signaling events 
downstream of nutrient induced switches in 
microbiota function and ChREBP/MondoA-Mlx 
activity, are of great interest for the future studies. 
In fact, the gut microbiota has already been shown 
to regulate ChREBP activity (Backhed et al. 2004). 
 
Tissue-specific knockout/knockdown models are 
likely to uncover some of the gut-specific roles of 
ChREBP/MondoA-Mlx, and Drosophila provides 
an optimal model to study them. Overall, 
Drosophila serves as an excellent cost-efficient 
model also for screening new regulators of glucose 
metabolism. A recent in vivo study identified more 
than 160 new genes regulating circulating glucose 
levels in Drosophila in a tissue-specific manner 
(Ugrankar et al. 2015). Of the characterized hits, 
more than 70 were novel candidates, and a 
conserved function for Ck1alpha in regulating 
glucose metabolism was also shown in mammals. 
This “glucome screen” study highlights the power 
of Drosophila as a model to pinpoint not only new 
metabolic regulators, but also their sites of function.  
5.4. The emerging roles of ChREBP/MondoA-
Mlx in human metabolic diseases 
Since their discovery, the dysregulation of 
ChREBP and MondoA has been linked to various 
human diseases and metabolic phenotypes. 
However, the data are still limited, and it seems that 
the dysregulation of ChREBP leads to distinct 
phenotypes in different tissues. Whereas increased 
ChREBP activity in the liver has been linked to 
elevated DNL, obesity and insulin resistance, in 
adipose tissue ChREBP appears to have a 
protective function against the development of 
insulin resistance (Herman et al. 2012; Eissing et al. 
2013; Kursawe et al. 2013). It has been also shown 
that both liver specific and whole-body inhibition 
of ChREBP not only alleviates the hepatic steatosis 
of ob/ob mice, but also improves the whole-body 
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glucose tolerance and insulin sensitivity (Dentin et 
al. 2006; Iizuka et al. 2006). On the other hand, the 
whole-body deficiency of ChREBP leads to 
reduced hepatic DNL and insulin resistance in mice 
(Iizuka et al. 2004). Although elevated hepatic 
DNL has been shown to contribute to the 
development of NAFLD and insulin resistance 
(Donnelly et al. 2005; Ameer et al. 2014), increased 
triglyceride accumulation and hepatic steatosis do 
not always lead to insulin resistance. In fact, it has 
been suggested that ChREBP activity is the factor 
that dissociates benign hepatic steatosis from 
insulin resistance, and that increased ChREBP 
activity in the liver also protects against insulin 
resistance (Benhamed et al. 2012).  
 
The classical view of obesity as the cause of insulin 
resistance has also been challenged by a number of 
studies that have shown a protective role for certain 
lipid species and their appropriate storage in the 
white adipose tissue against the development of 
insulin resistance (Stefan et al. 2008; Lodhi et al. 
2011). The protective role for fat body lipogenesis 
against the harmful consequences of high-sugar diet 
feeding has been also shown in Drosophila 
(Musselman et al. 2013). Lipotoxicity, a condition 
of lipid overload in adipose tissue leading to 
increased lipid intermediates in blood and non-
adipose tissue, in turn has been suggested to 
contribute to the development of metabolic and 
cardiovascular diseases (Unger et al. 2010). 
Lipotoxicity is characterized especially by the 
accumulation of ceramides, which are thought to be 
among the most harmful lipid metabolites in the 
development of metabolic disorders (Chaurasia and 
Summers 2015). Increased plasma and skeletal 
muscle ceramide levels are observed in type 2 
diabetes (Adams et al. 2004; Haus et al. 2009). 
Interestingly, our metabolic profiling of mlx1 
mutant animals revealed an increase in ceramide 
levels, suggesting that Mondo-Mlx plays an 
important role in the development of lipotoxicity 
and in sphingolipid biosynthesis. Our RNAseq data 
also showed that Mondo-Mlx is regulating the 
expression of serine palmitoyl transferase subunits 
Spt-I and lace, which are the rate limiting enzymes 
of the sphingolipid biosynthesis pathway. 
Moreover, we found that the sugar-induced 
expression of perilipins (Lsd-1 and Lsd-2) was 
dependent on Mondo-Mlx. Lipid droplet formation, 
and more specifically perilipins, are suggested to 
play a protective role against lipotoxicity (Borg et 
al. 2009). Our data suggest that Mondo-Mlx is 
regulating the delicate balance between healthy 
lipid storage and toxic overspill of lipid 
intermediates into other tissues at multiple levels, 
including de novo lipogenesis, lipid storage and 
biosynthesis of sphingolipids. The beneficial role 
for Mondo-regulated lipogenesis is supported also 
by another study, which demonstrated that Mondo-
dependent lipogenesis in the fat body protects from 
high sugar diet induced hyperglycemia (Musselman 
et al. 2013). 
 
The distinct outcomes of increased ChREBP 
activity in different tissues, and also the 
contradictory studies on modulation of ChREBP 
activity in the liver, have taught us a great deal 
about the pathogenesis of metabolic diseases such 
as hepatic steatosis and type 2 diabetes. The 
complex interplay between different metabolic 
organs and environmental and genetic factors is 
likely to dictate the ultimate metabolic outcomes. It 
seems that ChREBP plays a major role in the 
development of many metabolic diseases, and we 
are only beginning to understand its role in these 
processes. Altogether, the existing studies suggest 
that modulation of ChREBP activity holds great 
promise as a therapeutic strategy to treat human 
metabolic diseases. 
5.5. Evolutionary view on sugar sensing 
Human diet has changed dramatically from 
traditional hunter-gatherers to agricultural societies 
and further to modern Western diet. Although the 
diet of hunter-gatherers showed great variation 
depending on the environment and culture, 
compared to modern human diet, the relatively low 
amount of carbohydrates was a universal feature 
(Cordain et al. 2000).  
 
The changes in the dietary behavior are also 
reflected at the genetic level. A common example 
is the lactase enzyme that breaks down milk-sugar 
lactose. The production of lactase enzyme declines 
after weaning in all mammals including humans 
(Sebastio et al. 1989). However, some humans are 
lactate persistent, a trait that is particularly common 
in some parts of the world, for example Northern 
Europe (Ingram et al. 2009; Itan et al. 2010). 
Lactose persistence has been suggested to have 
evolved in cultures where dairy products are 
consumed in high quantities, and current models 
trace the mutation associated with the lactase 
persistence trait back to the time of animal 
domestication (Enattah et al. 2002; Bersaglieri et al. 
2004; Tishkoff et al. 2007; Evershed et al. 2008). 
Another interesting example of the evolution of 
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metabolic enzymes in humans is the positive 
selection on salivary amylase (AMY1) gene copy 
number, which correlates positively with human 
populations that have favored a high-starch diet 
(Perry et al. 2007). Whereas the Neanderthals had 
only one copy of AMY1, over 98% of modern 
humans carry multiple copies of the gene (Perry et 
al. 2007; Prufer et al. 2014). 
  
The modern Western diet is characterized by a high 
amount of carbohydrates, estimated to contribute as 
much as 50% of the total calories in a typical 
American diet (Freedman et al. 2001; Wright and 
Wang 2010). The increasing consumption of sugar 
has been proposed to underlie the increase in 
prevalence of metabolic diseases world-wide, and 
according to the newest guideline of the World 
Health Organization (WHO), the daily intake of 
added sugars should not exceed 10% of total energy 
intake. The increasing consumption of fructose, 
especially from sugar-sweetened beverages, has 
been suggested to be the major contributing factor 
to the obesity epidemic and to obesity-related 
diseases (Lustig et al. 2012). Fructose is 
metabolized by the liver, and high fructose 
consumption has been shown to increase hepatic 
DNL, compromise hepatic insulin sensitivity and to 
contribute to the development of lipotoxicity 
(Mayes 1993; Le et al. 2009; Stanhope et al. 2009; 
Tappy and Le 2010; Lustig et al. 2012; Stanhope 
2012). We found that the mlx1 mutants are 
intolerant to both glucose and fructose, suggesting 
that Mondo-Mlx activity is required for proper 
metabolism of both. Liver ChREBP activity in rats 
has been shown to respond more strongly to 
fructose than glucose (Koo et al. 2009). It has been 
also recently suggested that fructose is a much more 
potent activator of the newly identified ChREBP-β 
isoform (Stamatikos et al. 2016). However, the role 
of Mondo proteins in mediating the specific 
metabolic effects of different sugars are still largely 
unknown.  
 
 
???????????breeder D. mojavensis, has been also 
shown to 
display intolerance to high sugar diet (Matzkin et al. 
2011). It will be interesting to learn what are the 
genetic mechanisms underlying the sugar 
intolerance of D. mojavensis. The genetic analysis 
of closely related species that differ in their dietary 
preferences provides an interesting way to discover 
the mechanisms defining the macronutrient spaces 
of different animals. Similarly, the analysis of 
human populations or individuals that show 
different responses to dietary interventions is 
invaluable for understanding the variation observed 
between individuals in their response to different 
dietary interventions. The example of individuals 
carrying a CRY variant and displaying a high 
carbohydrate diet-dependent risk of developing 
insulin resistance (Dashti et al. 2014) suggests that 
in order to manage metabolic diseases such as type 
2 diabetes, we must understand how genetic 
background interacts with the diet. Certain variants 
of ChREBP have been shown to correlate with 
increased circulating triglyceride levels, a known 
risk factor for developing insulin resistance and 
type 2 diabetes (Kathiresan et al. 2008; Kooner et 
al. 2008; Wang et al. 2008; Willer et al. 2008; Pan 
et al. 2009). However, the underlying target genes 
of ChREBP causing the altered lipid profiles have 
remained largely undiscovered. We showed that 
comparing the Drosophila Mondo-Mlx regulated 
transcriptome data to genome-wide association 
studies (GWAS) can reveal putative causal genes. 
Comparisons of existing GWAS data sets to 
functional studies holds a great promise on 
revealing new potential therapeutic target genes. 
 
Another layer of complexity comes from the 
discovery that acquired traits can be inherited. It has 
been shown in several studies that diet induces 
metabolic reprogramming via chromatin 
remodeling, and that these epigenetic changes can 
be also transmitted to the progeny (Ng et al. 2010; 
Fullston et al. 2013; Leung et al. 2014; Ost et al. 
2014). For example, excessive weight gain in early 
childhood increases the likelihood of developing 
type 2 diabetes and obesity in the next generation, 
independent of parental adult obesity (Li et al. 
2009a). Moreover, these epigenetic modifications 
seem to be dependent on genetic background 
(Leung et al. 2014). Whereas personalized 
medicine as a concept is widely acknowledged to 
be critical in treating certain diseases, personalized 
nutrition as a practice to manage metabolic diseases 
is only now emerging.  
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There is no evolution without variation (Darwin 
1859). It is clear that species, populations and 
individuals within them, differ in their metabolism 
and responses to different diets. This is crucial for 
adaptation, but also displays a challenge for treating 
metabolic diseases. Understanding the complex 
interplay between genetics, epigenetics and diet is 
the key for developing personalized therapies for 
metabolic disorders.  
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